<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mammary Gland Biol Neoplasia</journal-id><journal-id journal-id-type="iso-abbrev">J Mammary Gland Biol Neoplasia</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Journal of Mammary Gland Biology and Neoplasia</journal-title></journal-title-group><issn pub-type="ppub">1083-3021</issn><issn pub-type="epub">1573-7039</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474719</article-id><article-id pub-id-type="pmcid-ver">PMC12474719.1</article-id><article-id pub-id-type="pmcaid">12474719</article-id><article-id pub-id-type="pmcaiid">12474719</article-id><article-id pub-id-type="pmid">41003863</article-id><article-id pub-id-type="doi">10.1007/s10911-025-09585-5</article-id><article-id pub-id-type="publisher-id">9585</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Does microtubule motor-mediated centrosomal dyshomeostasis confer chemoresistance in breast cancer?</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Priyanga</surname><given-names initials="J">J.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Guha</surname><given-names initials="G">Gunjan</given-names></name><address><email>gunjan.doc@gmail.com</email><email>gunjanguha@scbt.sastra.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bhakta-Guha</surname><given-names initials="D">Dipita</given-names></name><address><email>dipita2001@gmail.com</email><email>dipitaguha@scbt.sastra.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/032jk8892</institution-id><institution-id institution-id-type="GRID">grid.412423.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0369 3226</institution-id><institution>Department of Biotechnology, </institution><institution>Cellular Dyshomeostasis Laboratory, School of Chemical and Bio Technology, SASTRA University, </institution></institution-wrap>Thanjavur, Tamil Nadu 613 401, India </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>30</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">497685</issue-id><elocation-id>14</elocation-id><history><date date-type="received"><day>4</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 14:25:15.427"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10911_2025_Article_9585.pdf"/><abstract id="Abs1"><p id="Par1">Chemoresistance is a major challenge in effective chemotherapy for breast cancers. Unfortunately, the precise molecular mechanisms that confer resistance remain elusive so far. A remarkable feature in a multitude of breast cancers is the presence of clustered supernumerary centrosomes, which is a dysregulated condition that arises primarily through centrosome over-duplication. Normally, microtubule motor proteins (MiMos) maintain the integrity of centrosomes <italic toggle="yes">via</italic> regulating cohesion, separation and positioning of centrosomes. In the recent years, several MiMos have been reported to be differentially expressed in chemoresistant breast cancers. Such findings suggest a probable association of MiMos with chemoresistance. Here, we propose that MiMo-associated centrosomal dysregulation is involved in conferring chemoresistance in breast cancers. We corroborate the same with a systematic review of literature where we narrow down to sixteen MiMos (one dynein and fifteen kinesins). Our argument highlights a plausible decisive role of MiMo-mediated centrosomal anomalies in orchestrating chemoresistance in breast cancers.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Chemoresistance</kwd><kwd>Centrosomal Dyshomeostasis</kwd><kwd>Supernumerary Centrosomes</kwd><kwd>Microtubule Motor Proteins</kwd><kwd>Systematic Review</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001409</institution-id><institution>Department of Science and Technology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><award-id>YSS/2014/000139</award-id><award-id>YSS/2015/000025</award-id><principal-award-recipient><name name-style="western"><surname>Guha</surname><given-names>Gunjan</given-names></name><name name-style="western"><surname>Bhakta-Guha</surname><given-names>Dipita</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001407</institution-id><institution>Department of Biotechnology, Ministry of Science and Technology, India</institution></institution-wrap></funding-source><award-id>BT/PR22434/MED/30/1901/2017</award-id><award-id>BT/PR22434/MED/30/1901/2017</award-id><principal-award-recipient><name name-style="western"><surname>Guha</surname><given-names>Gunjan</given-names></name><name name-style="western"><surname>Bhakta-Guha</surname><given-names>Dipita</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Breast cancer is one of the leading causes of death among women and, in 2020 alone, claimed around 0.685&#160;million lives worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. At present, the common intervention modalities for breast cancer include chemotherapy, surgery, radiation and endocrine therapy, where chemotherapy dominates as the most adopted approach [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Taxanes (docetaxel and paclitaxel) and anthracyclines (doxorubicin, epirubicin, etc.), are some of the first line of chemotherapeutics that showcase considerable efficacy across different stages/grades of breast cancer [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. However, a major challenge that plagues this approach is the development of chemoresistance by cancer cells. This not only renders the <italic toggle="yes">prima facie</italic> treatment ineffective, but also augments the risk of relapse along with lowered survival probability in the patients [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Hence, understanding the mechanisms that are involved in the development of chemoresistance can ensure implementation of strategies aimed at sustained sensitization of cancer cells to chemotherapy. This, in turn, will enable us toward a plausible progress in the cancer therapy paradigm and subsequently drive ourselves forward in achieving &#8216;good health and well being&#8217; &#8211; one of the seventeen sustainable development goals of the United Nations (UN-SDG) [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par3">Akin to the etiology of cancer, rise of chemoresistance, in cancer cells, is a consequence of complex dysregulation of various cellular facets [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In case of breast cancer cells, among a host of functional proteins which participate in the development of chemoresistance, a few critical centrosome-associated proteins have been reported to be deregulated [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. This suggests that centrosomal anomalies might play a decisive role in promoting chemoresistance in breast cancers. However, the precise role of dysregulated centrosomal function in chemoresistance is still obscure.</p><p id="Par4">Centrosome, present in a single copy in an non-dividing cell, is the microtubule-organizing center (MTOC) of animal cells, and is primarily responsible for cell division [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. A cell undergoing division encloses a pair of centrosomes, which form two opposite poles of the spindle apparatus [<xref ref-type="bibr" rid="CR18">18</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a). Such bipolar spindle assembly ensures that sister chromatids are accurately separated in order to subsequently give rise to healthy daughter cells. Controlled regulation of the number and structure of centrosome is therefore a prerequisite that ensures error-free chromosome segregation during cell division [<xref ref-type="bibr" rid="CR19">19</xref>]. To ascertain this, duplication of centrosome is stringently orchestrated by a plethora of centrosomal proteins, such as <italic toggle="yes">NLP</italic>, <italic toggle="yes">NEK2</italic> and <italic toggle="yes">PLK4</italic> [<xref ref-type="bibr" rid="CR20">20</xref>]. Any inadvertent irregularity in the centrosome duplication process categorically promotes genomic instability, which is a salient hallmark of cancer cells [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. It is to be underscored that breast cancer cells commonly harbor centrosomal anomalies, be it structural, positional and/or numerical [<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref>]. In the case of erroneous duplication of centrosome, numerical anomalies (overduplication) can occur, which can produce more than two centrosomes [called supernumerary centrosomes (SNCs)] in a mitotic cell [<xref ref-type="bibr" rid="CR24">24</xref>]. SNCs promote formation of multipolar spindles (instead of bipolar configuration); consequently triggering mitotic catastrophe and cell death (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b). However, a large number of cancer cells, that harbor SNCs, circumvent mortality by mimicking the bipolar spindle arrangement of normal cells [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Such pseudo-bipolar spindle assembly is formed by a phenomenon called centrosome clustering (CC), where multiple centrosomes are aggregated at two opposite poles, rather than forming the expected multipolar spindle apparatus (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>c). Consequently, such cancer cells thrive, albeit with anomalies, which in turn, manifest into genomic instability.</p><p id="Par5">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Supernumerary centrosome-governed multipolar spindle formation and subsequent mitotic catastrophe are avoided by breast cancer cells <italic toggle="yes">via</italic> centrosome clustering. <bold>a</bold>&#160;Normal cells divide successfully with a bipolar spindle assembly that is constructed by a pair of centrosomes (binary). <bold>b</bold>&#160;If supernumerary centrosomes are produced in normal cells due to dysregulated centrosome duplication cycle, a multipolar spindle arrangement is formed, which fails to facilitate cell division. In such cases, cell division is aborted prematurely in a mitotic catastrophe, and the cell dies. <bold>c&#160;</bold>Many breast cancers harbor supernumerary centrosomes. However, they avoid mitotic catastrophe by evading multipolar spindle formation. This is implemented by clustering supernumerary centrosomes in a pseudo-bipolar conformation, which mimics the bipolar spindle assembly of normal cells, thereby allowing the cancer cells to survive</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="10911_2025_9585_Fig1_HTML.jpg"/></fig>
</p><p id="Par6">An important class of regulators that maintain centrosome fidelity is the microtubule motor proteins (MiMos). Based on their directional movement, MiMos are classified into two large families: kinesins (plus end-directed) and dyneins (minus end-directed) [<xref ref-type="bibr" rid="CR27">27</xref>]. In principle, these kinesins and dyneins facilitate transportation of vesicles and organelles along microtubules (cytoskeletal element) in cells [<xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref>]. Several previous studies have associated dysregulation of MiMos with chemoresistance in a variety of cancers such as colorectal [<xref ref-type="bibr" rid="CR31">31</xref>], prostate [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], lungs [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], liver [<xref ref-type="bibr" rid="CR36">36</xref>] and breast cancers [<xref ref-type="bibr" rid="CR37">37</xref>&#8211;<xref ref-type="bibr" rid="CR39">39</xref>]. In our recent publication, we have highlighted the contribution of anomalous MiMo expressions to centrosomal abnormalities in diverse cancers [<xref ref-type="bibr" rid="CR26">26</xref>]. However, the plausible association of chemoresistance and MiMo-mediated centrosomal anomalies in breast cancer has not been explored so far. This encourages us to propose our present hypothesis, which has been discussed in the following sections.</p></sec><sec id="Sec2"><title>Proposed hypothesis</title><p id="Par7">MiMos play a central role in maintaining centrosome homeostasis [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], while also being implicated in chemoresistance [<xref ref-type="bibr" rid="CR37">37</xref>&#8211;<xref ref-type="bibr" rid="CR39">39</xref>]. Almost 80% of breast tumors possess SNCs (due to lack of centrosome homeostasis), which contribute to cancer cell survival [<xref ref-type="bibr" rid="CR19">19</xref>]. Unfortunately, although several reports have correlated centrosomal abnormalities with cancer initiation and progression, very few have endeavored to focus on centrosomal dyshomeostasis as a chief contributor to chemoresistance in breast cancers [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Therefore, it becomes prudent to explore if MiMo-mediated centrosomal anomalies play a deterministic role in conferring chemoresistance to breast cancer cells. Hence, we hypothesize that <italic toggle="yes">MiMos contribute to chemoresistance by modulating centrosomal homeostasis in breast cancers</italic>. To support this hypothesis, we have carried out a systematic review on MiMos that remain differentially expressed in chemoresistant breast cancers. In tandem to this, analyzing reports from various research groups as well as our previously published study [<xref ref-type="bibr" rid="CR26">26</xref>], we know that MiMos also have an important role in maintaining centrosomal homeostasis. Collectively, we attempt to envisage whether perturbation of MiMo-mediated centrosomal function might be responsible for conferring chemoresistance in breast cancers.</p></sec><sec id="Sec3"><title>Systematic review</title><sec id="Sec4"><title>Search strategy</title><p id="Par8">The systematic review was conducted according to the guidelines of &#8220;preferred reporting items for systematic reviews and meta-analyses&#8221; (PRISMA) [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> denotes the methods of identification, screening, exclusion and selection of studies in accordance to the PRISMA guidelines. Two databases, viz. PubMed, Cochrane Database of Systematic Reviews (CDSR) were searched using the following keyword syntaxes.</p><p id="Par9">
<list list-type="bullet"><list-item><p id="Par10">((name/alternate names of MiMo) AND (drug-resistant/drug resistance)) AND (breast cancer)</p></list-item><list-item><p id="Par11">((name/alternate names of MiMo) AND (chemoresistant/chemoresistance)) AND (breast cancer)</p></list-item><list-item><p id="Par12">((name/alternate names of MiMo) AND (drug sensitivity)) AND (breast cancer)</p></list-item></list>
</p><p id="Par13">Data and relevant information were extracted from the included publications, and were examined for qualitative integrity in the light of how that may affect the synthesis of results. Thereafter, results were narratively synthesized by summarizing the findings from each study in a clear and concise manner. The synthesized results were assessed to evaluate the strength of evidence relevant to this study, while acknowledging any limitations in these results.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Identification of relevant publications from online databases and registers for systematic review in agreement with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Out of 39 results returned by applicable syntax search, we included 12 articles in the systematic review (after screening and elimination of duplicates and other irrelevant publications). All selection and screening criteria are enlisted</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10911_2025_9585_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Inclusion criteria</title><p id="Par14">Research articles with data pertinent to deregulation of MiMo expression in chemoresistant breast cancer cells and patient samples were selected for this study. Both qualitative and quantitative data on the expression profile of MiMos in chemoresistant breast cancer cell lines and breast cancer patient samples were assessed.</p></sec><sec id="Sec6"><title>Exclusion criteria</title><p id="Par15">The following results were excluded from the study: (i) Research articles about chemoresistance in other cancer types (i.e. apart from breast cancer) were excluded. (ii) Review articles commenting exclusively on MiMos, MiMo inhibitors and chemotherapy were rejected. (iii) Abstracts from conference proceedings were not included for this study.</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par16">While CDSR did not yield any results, PubMed returned 39 hits. Following screening and exclusion (in accordance to the PRISMA criteria mentioned in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), fourteen full-text articles were selected. Out of these, two research articles [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] were rejected. The first article that we rejected was the one published by Zhang et al.&#160;[<xref ref-type="bibr" rid="CR46">46</xref>] since the article did not present any information on the expression profiles of MiMos that contributes to chemoresistance. Another article by Rodrigues-Ferreira et al.&#160;[<xref ref-type="bibr" rid="CR47">47</xref>] was excluded as this article exhibited a list of kinesins that remain differentially regulated in chemo sensitive breast tumors without providing any insight into the expression profiles of MiMos and their <italic toggle="yes">modus operandi</italic> in influencing chemoresistance. Finally, we had twelve, relevant, full-text articles with data pertinent to deregulation of MiMo expression in chemoresistant breast cancer cells and patient samples. From these articles, we shortlisted sixteen pertinent MiMos, whose expressions were reported to be altered in chemoresistant breast cancers. In the following sections, to support our proposed hypothesis, we first explored the association between MiMos and chemoresistance in breast cancer using systematic literature review.</p><sec id="Sec8"><title>Association of MiMos with chemoresistance in breast cancer</title><p id="Par17">In the systematic review, we determined sixteen MiMos that remain altered in chemoresistant breast cancers. Among them, there is one dynein (dynein light intermediate chain-1; <italic toggle="yes">DYNLL1</italic>) and fifteen kinesins (<italic toggle="yes">KIF1A</italic>, <italic toggle="yes">KIF2C</italic>, <italic toggle="yes">KIF3A</italic>, <italic toggle="yes">KIF4A</italic>, <italic toggle="yes">KIF5A</italic>, <italic toggle="yes">KIF11</italic>, <italic toggle="yes">KIF12</italic>, <italic toggle="yes">KIF13B</italic>, <italic toggle="yes">KIF14</italic>, <italic toggle="yes">KIF15</italic>, <italic toggle="yes">KIF18A</italic>, <italic toggle="yes">KIF20A</italic>, <italic toggle="yes">KIF23</italic>, <italic toggle="yes">KIFC1</italic> and <italic toggle="yes">KIFC3</italic>). Each of them has been found to demonstrate association with resistance against specific breast cancer-chemotherapeutics (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). A detailed account of common chemotherapy drugs that might trigger MiMo-associated chemoresistance is mentioned below.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>MiMos associated with resistance against specific chemotherapy drugs in breast cancers. Breast cancer cells demonstrating resistance toward doxorubicin, paclitaxel, docetaxel, tamoxifen or monastrol show altered expressions of particular MiMos. Altogether, a group of sixteen MiMos (one dynein and fifteen kinesins) are associated with chemoresistance in breast cancers</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10911_2025_9585_Fig3_HTML.jpg"/></fig></p><p id="Par18"><italic toggle="yes">Tamoxifen</italic> is a non-steroidal, anti-estrogenic drug that is commonly recommended to estrogen-receptor positive (ER+) breast cancer patients. In principle, estradiol (a type of estrogen) promotes proliferation of breast cancer cells by binding to ER. Tamoxifen competes with estradiol to bind to ER, in breast tissues, and subsequently exhibits antitumor effect [<xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref>]. However, 20&#8211;30% of these tumors reportedly develop resistance toward the drug [<xref ref-type="bibr" rid="CR52">52</xref>]. Interestingly, elevated expressions of four kinesins &#8211;&#8211; <italic toggle="yes">KIF4A</italic>, <italic toggle="yes">KIF15</italic>, <italic toggle="yes">KIF20A</italic> and <italic toggle="yes">KIF23</italic> &#8211;&#8211; were deemed to be responsible for tamoxifen-resistance in breast cancer, while demonstrating strong correlations with poor prognosis and tumor recurrence [<xref ref-type="bibr" rid="CR53">53</xref>]. It is to be noted that the expressions of a number of kinesins are known to be governed by estradiol [<xref ref-type="bibr" rid="CR54">54</xref>]. Estradiol stimulates the transcriptional regulator <italic toggle="yes">ANCCA</italic> (AAA&#8201;+&#8201;nuclear co-regulator cancer associated protein), which is an ATPase coactivator for ER&#945; [<xref ref-type="bibr" rid="CR54">54</xref>]. Upon estradiol stimulation, <italic toggle="yes">ANCCA</italic> is recruited to the promoter of <italic toggle="yes">KIF4A</italic>, <italic toggle="yes">KIF15</italic>, <italic toggle="yes">KIF20A</italic> and <italic toggle="yes">KIF23</italic> encoding genes, and induces methylation of the Lys-4 residue of histone H3 protein (H3K4). This methylation, in turn, facilitates assembly of RNA polymerase II for transcription of the four kinesins in tamoxifen-resistant tumors. Therefore, knockdown of <italic toggle="yes">KIF4A</italic>, <italic toggle="yes">KIF15</italic>, <italic toggle="yes">KIF20A</italic> and <italic toggle="yes">KIF23</italic> genes increased the sensitivity of breast cancer cells to tamoxifen [<xref ref-type="bibr" rid="CR53">53</xref>]. Hence, an estradiol/<italic toggle="yes">ANCCA</italic>-mediated elevation in the expressions of these four kinesins might be responsible for tamoxifen-resistance in breast cancers [<xref ref-type="bibr" rid="CR53">53</xref>]. In another study, <italic toggle="yes">KIF18A</italic>, which usually remains overexpressed in breast cancer, has also been correlated with poor prognosis and reduced survival rate of ER&#8201;+&#8201;breast cancer patients (treated with tamoxifen) [<xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par19">Another commonly administered chemotherapy drug, <italic toggle="yes">doxorubicin</italic>, is known to kill cancer cells by DNA intercalation [<xref ref-type="bibr" rid="CR56">56</xref>]. However, resistance toward doxorubicin is a major contributor to increased mortality in breast cancer patients [<xref ref-type="bibr" rid="CR57">57</xref>]. Intriguingly, silencing of <italic toggle="yes">KIF3A</italic> has been shown to augment sensitization of breast cancer cells to doxorubicin [<xref ref-type="bibr" rid="CR58">58</xref>]. Moreover, doxorubicin could induce <italic toggle="yes">KIF14</italic> expression in triple-negative breast cancer (TNBC) patients, and contributed to resistance toward therapy [<xref ref-type="bibr" rid="CR39">39</xref>]. However, the precise mechanisms that facilitate <italic toggle="yes">KIF3A</italic> and <italic toggle="yes">KIF14</italic> to confer doxorubicin-resistance are still not clearly understood. According to a recent study by Jiang and colleagues (2021), another kinesin, <italic toggle="yes">KIF2C</italic> was found to be overexpressed in tissues and cells of doxorubicin-resistant breast cancer. In these resistant cancers, increased expression of <italic toggle="yes">KIF2C</italic> is associated with reduced expression of T-box transcription factor-15 (<italic toggle="yes">TBX15</italic>) and microRNA-152 (miR-152). <italic toggle="yes">KIF2C</italic> contributes to drug resistance by binding to pyruvate kinase M2 (<italic toggle="yes">PKM2</italic>). <italic toggle="yes">PKM2</italic> is responsible of anaerobic glycolysis and its expression is augmented in several malignancies including breast cancer. Binding of <italic toggle="yes">KIF2C</italic> to <italic toggle="yes">PKM2</italic> prevents ubiquitin-mediated degradation of <italic toggle="yes">PKM2</italic>, and contributes to the latter&#8217;s stability. This, in turn, is responsible for doxorubicin-resistance in breast cancer. Overexpression of miR-152 could suppress the expression of <italic toggle="yes">KIF2C</italic> and <italic toggle="yes">PKM2</italic> and thus does not allow doxorubicin resistance in breast cancer [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par20"><italic toggle="yes">Taxanes</italic> (<italic toggle="yes">paclitaxel</italic> and <italic toggle="yes">docetaxel</italic>) bind to the &#946;-subunit of tubulin heterodimer and increase microtubule polymerization. Such altered microtubule dynamics initiate improper spindle formation during mitosis, which in turn, triggers apoptosis [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. While common chemotherapeutic drugs (such as, <italic toggle="yes">tamoxifen</italic> or <italic toggle="yes">herceptin</italic>) fail to treat TNBCs (due to their lack of receptors for estrogen, progesterone and <italic toggle="yes">HER2</italic>), taxanes emerge as an effective option [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Nevertheless, resistance to taxanes is regularly reported as a chief hindrance to intervention [<xref ref-type="bibr" rid="CR64">64</xref>], often due to the involvement of MiMos. For instance, altered expressions of <italic toggle="yes">DYNLL1</italic>, <italic toggle="yes">KIF13B</italic>, <italic toggle="yes">KIF20A</italic>, <italic toggle="yes">KIF14</italic> and <italic toggle="yes">KIFC3</italic> have been associated with paclitaxel chemoresistance in breast cancers, concurrently promoting poor prognosis. Among the above-mentioned MiMos, the dynein alone is found to be diminished in paclitaxel-resistant breast cancer cells, while the four kinesins are usually overexpressed in these cells [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR65">65</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>]. Overexpression of <italic toggle="yes">KIF20A</italic> in paclitaxel-resistant breast cancers is reportedly induced by its upstream regulator <italic toggle="yes">FOXM1</italic>, a member of the forkhead box (FOX) family of transcription factors. Inhibition of interaction between <italic toggle="yes">FOXM1</italic> and the forkhead response element (<italic toggle="yes">FHRE</italic>) in the <italic toggle="yes">KIF20A</italic> gene can sensitize breast cancer cells toward paclitaxel [<xref ref-type="bibr" rid="CR67">67</xref>]. The molecular mechanics involving <italic toggle="yes">DYNLL1</italic>, <italic toggle="yes">KIF13B</italic>, <italic toggle="yes">KIF14</italic> and <italic toggle="yes">KIFC3</italic> in developing paclitaxel-resistant breast cancers remain unclear. Docetaxel-resistant breast cancer cells, on the other hand, display augmented expressions of <italic toggle="yes">KIF1A</italic> [<xref ref-type="bibr" rid="CR37">37</xref>], <italic toggle="yes">KIF5A</italic>, <italic toggle="yes">KIF12</italic>, <italic toggle="yes">KIFC1</italic>, <italic toggle="yes">KIFC3</italic> [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] and <italic toggle="yes">KIF14</italic> [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. No dynein has been seen to be associated with chemoresistance toward docetaxel. While not much information is available on how <italic toggle="yes">KIF1A</italic>, <italic toggle="yes">KIF5A</italic>, <italic toggle="yes">KIF12</italic>, <italic toggle="yes">KIFC1</italic> and <italic toggle="yes">KIFC3</italic> participate in developing docetaxel-resistance, <italic toggle="yes">KIF14</italic> phosphorylates <italic toggle="yes">AKT</italic> (at S473 and T308 residues) in docetaxel-resistant breast cancer cells. Dephosphorylation of <italic toggle="yes">AKT</italic> in such cells were, understandably, seen to sensitize them to docetaxel [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par21">Another breast cancer drug, <italic toggle="yes">monastrol</italic>, inhibits microtubule ATP hydrolysis, thereby promoting mitotic arrest [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Despite its cytotoxic effect against breast cancer cells, monastrol resistance has been abundantly reported. In such monastrol-resistant cells, <italic toggle="yes">KIF11</italic> has been found to be significantly overexpressed [<xref ref-type="bibr" rid="CR71">71</xref>]. Normally, CirRNA-<italic toggle="yes">MTO1</italic> (circular RNA formed due to the back splicing of the mitochondrial tRNA translation optimization 1 gene transcript) inhibits <italic toggle="yes">TRAF4</italic> (inducer of KIF11), thereby inhibiting <italic toggle="yes">KIF11</italic> as well [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. As expected, monastrol-resistant breast cancer cells demonstrate decreased abundance of CirRNA-<italic toggle="yes">MTO1</italic>, which leads to <italic toggle="yes">KIF11</italic> overexpression. However, the precise role of <italic toggle="yes">KIF11</italic> overexpression in modulating monastrol resistance in breast cancers has still not been deciphered.</p></sec></sec><sec id="Sec9"><title>MiMo-associated chemoresistance and centrosome homeostasis: a crucial connection</title><p id="Par22">Centrosomal dyshomeostasis is inextricably linked to various phenomena in breast cancer namely aneuploidy, tumorigenesis, immune evasion, metastasis, and disease aggressiveness [<xref ref-type="bibr" rid="CR73">73</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>]. In cancer cells, structural and numerical anomalies of the centrosome are abundant, particularly in high-grade tumors and TNBCs [<xref ref-type="bibr" rid="CR77">77</xref>]. Now, centrosome homeostasis to a huge extent is governed by MiMos, established by the fact that MiMos are involved in controlling centrosome separation, centrosome positioning, maintenance of pericentriolar matrix, and centrosome cohesion [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR78">78</xref>&#8211;<xref ref-type="bibr" rid="CR81">81</xref>]. It is, therefore, judicious to assume that the three, apparent independent facets (MiMos, centrosome homeostasis and chemoresistance) might actually be hands-in-glove in assuring the failure of chemosensitization in breast cancers. Concurrently, as our systematic review revealed, sixteen MiMos were commonly associated with chemoresistance in breast cancer. It is important to note that, seven among them [the dynein <italic toggle="yes">DYNLL1</italic> and six kinesins (<italic toggle="yes">KIF2C</italic>, <italic toggle="yes">KIF11</italic>, <italic toggle="yes">KIF15</italic>, <italic toggle="yes">KIF18A</italic>, <italic toggle="yes">KIFC1</italic> and <italic toggle="yes">KIFC3</italic>)] are directly involved in maintaining structural and functional integrity of the centrosome [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR82">82</xref>&#8211;<xref ref-type="bibr" rid="CR89">89</xref>]. Herein, we understand how the MiMos obtained through our preliminary search are associated with centrosomal homeostasis.</p><p id="Par23"><italic toggle="yes">DYNLL1</italic>, which is associated with paclitaxel resistance in breast cancer, is also responsible for the recruitment of centrosomal proteins (viz., &#947;-tubulin, and pericentrin) to the pericentriolar matrix of the centrosome. For centrosomes to nucleate microtubules, it requires various proteins (&#947;-tubulin, <italic toggle="yes">CG-NAP</italic>, kendrin [<xref ref-type="bibr" rid="CR90">90</xref>]) to be assembled onto centrosomes. <italic toggle="yes">DYNLL1</italic> binds to the centrosomal proteins and transport them to the centrosomes. Transport of these proteins by <italic toggle="yes">DYNLL1</italic> is further facilitated by dynactin (a multiprotein complex with different binding sites for cargo, microtubules and dynein [<xref ref-type="bibr" rid="CR91">91</xref>]). This assembly of proteins onto the centrosome is accountable for the nucleation of microtubules [<xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par24"><italic toggle="yes">KIF2C</italic>, <italic toggle="yes">KIF11</italic> and <italic toggle="yes">KIF15</italic>, in principle, are responsible for the separation and positioning of centrosomes in a mitotic cell and have also been seen to be involved in chemoresistance toward monastrol, tamoxifen and doxorubicin respectively [<xref ref-type="bibr" rid="CR82">82</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]. Separation of duplicated centrosomes, prior to mitosis, is vital to establish a precise bipolar spindle apparatus [<xref ref-type="bibr" rid="CR92">92</xref>]. During the onset of mitosis, <italic toggle="yes">KIF11</italic> crosslinks antiparallel microtubules and generates an outward force, which pushes the centrosomes toward two opposite poles, consequently perfecting the architecture of the bipolar spindle assembly. On the other hand, <italic toggle="yes">KIF15</italic> facilitates centrosome separation in absence of <italic toggle="yes">KIF11</italic> [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. A microtubule associated protein, <italic toggle="yes">TPX2</italic>, binds and cross-links two <italic toggle="yes">KIF15</italic>, creating a tetramer, which binds to microtubule and move the centrosomes apart. Although absence of <italic toggle="yes">KIF15</italic> does not affect the bipolar spindle assembly (established by <italic toggle="yes">KIF11</italic>) during mitosis, it becomes necessary when <italic toggle="yes">KIF11</italic> is absent [<xref ref-type="bibr" rid="CR85">85</xref>]. Similar to <italic toggle="yes">KIF15</italic>, <italic toggle="yes">KIF2C</italic> also governs bipolar spindle assembly in the absence of <italic toggle="yes">KIF11</italic>. <italic toggle="yes">KIF2C</italic> along with <italic toggle="yes">KIF18B</italic> maintains the length and number of astral microtubules emanating from the centrosome. The astral microtubules of the centrosome radiate toward the cortex and facilitate centrosome positioning during mitosis. The balance between nucleation and depolymerization of astral microtubule is necessary for proper bipolar spindle assembly. Aster depolymerization requires <italic toggle="yes">KIF18B</italic> and <italic toggle="yes">KIF2C</italic>, both of which possess plus-end microtubule depolymerizing activity. Lack of depolymerization (by <italic toggle="yes">KIF18B</italic> and <italic toggle="yes">KIF2C</italic>) leads to excessive nucleation of astral microtubules, and enhanced inward force on the centrosome. This promotes collision of aster microtubules with cortex. Therefore, it might be concluded that <italic toggle="yes">KIF2C</italic> govern centrosome positioning by maintaining a balance between nucleation and depolymerization of astral microtubules [<xref ref-type="bibr" rid="CR94">94</xref>].</p><p id="Par25">Another kinesin that is involved in tamoxifen-resistance is <italic toggle="yes">KIF18A</italic>, which also plays a role in maintaining chromosomal stability during mitosis. In aneuploid cells like TNBCs, knockdown of <italic toggle="yes">KIF18A</italic> has been seen to induce centrosome fragmentation [<xref ref-type="bibr" rid="CR89">89</xref>]. Meanwhile, overexpression of <italic toggle="yes">KIFC1</italic> (which is associated with docetaxel resistance) is involved in promoting the clustering of SNCs (by inducing centrosome cohesion) in breast cancer cells. Following nuclear envelope breakdown, <italic toggle="yes">KIFC1</italic>, along with an intraflagellar transport protein (<italic toggle="yes">IFT52</italic>), contributes to centrosome clustering by imparting cohesive force between SNCs [<xref ref-type="bibr" rid="CR88">88</xref>]. Also, <italic toggle="yes">KIFC3</italic>, which is correlated to both paclitaxel and docetaxel resistance, binds to microtubules of subdistal appendages of paired centrosomes (during G2 phase), and impart an inward cohesive force, which holds the centrosomes together [<xref ref-type="bibr" rid="CR80">80</xref>]. Since dysregulation of centrosome function can initiate and propagate breast cancer, it is logical to focus on centrosomal homeostasis in identifying inherent molecular mechanisms involved in the sustenance of these cancer cells. For instance, in order to avoid mitotic catastrophe, breast cancer cells with SNCs, evade multipolar spindle formation by CC in order to form pseudo-bipolar spindles [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. All of these evidences suggest that MiMos might play influential roles both in chemoresistance and centrosome regulation in breast cancers. Hence, it is prudent to explore them further from the perspective of a plausible functional connection between chemoresistance and centrosome homeostases.</p></sec><sec id="Sec10"><title>Epilogue</title><p id="Par26">The findings of our systematic review showed that deregulation of sixteen MiMos are commonly associated with chemoresistant breast cancers. Furthermore, we established that a multitude of MiMos are directly accountable for centrosomal homeostasis. However, there is a significant dearth of knowledge regarding the connection between dysregulated MiMos and their simultaneous contribution to centrosomal anomalies and chemoresistance in breast cancers. This indicates a potential association of MiMo-governed centrosomal defects in facilitating development of resistance toward chemotherapeutics. Thus, our hypothesis that &#8220;<italic toggle="yes">MiMos contribute to chemoresistance by modulating centrosomal homeostasis in breast cancers</italic><bold>&#8221;</bold> remains to be experimentally tested. This study is limited to a predictive analysis that would enable us to formulate a hypothesis; however, the actual potential of MiMos in being a determinant for chemoresistance can be validated only by carrying out in vitro and in vivo experiments. Exploration into the precincts of this hypothesis might provide novel insights, which might be crucial for developing new chemotherapeutics that may have greater intervention potential and reduced probability of resistance in breast cancer patients.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>J.P. wrote the original draft and worked on the methodology. G.G. worked on the conceptualization, data curation, validation, Supervision. D.BG. worked on the conceptualization, supervised, reviewed and corrected the original draft and also validated the same. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the Science and Engineering Research Board &#8211; Department of Science &amp; Technology Science (DST-SERB) [grant numbers YSS/2014/000139 (GG), YSS/2015/000025 (DBG); and the Department of Biotechnology (DBT) [grant number BT/PR22434/MED/30/1901/2017 (GG &amp; DBG)].</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par27">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><collab>Global Cancer Statistics 2020</collab></person-group><article-title>GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA</article-title><source>Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer Statistics 2020. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J Clin. 2021;71:209&#8211;49. 10.3322/caac.21660.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birnbaum</surname><given-names>JK</given-names></name><name name-style="western"><surname>Duggan</surname><given-names>C</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>BO</given-names></name><name name-style="western"><surname>Etzioni</surname><given-names>R</given-names></name></person-group><article-title>Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study</article-title><source>Lancet Glob Health</source><year>2018</year><volume>6</volume><fpage>e885</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(18)30257-2</pub-id><pub-id pub-id-type="pmid">30012269</pub-id><pub-id pub-id-type="pmcid">PMC6214657</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Birnbaum JK, Duggan C, Anderson BO, Etzioni R. Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. Lancet Glob Health. 2018;6:e885&#8211;93. 10.1016/S2214-109X(18)30257-2.<pub-id pub-id-type="pmid">30012269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(18)30257-2</pub-id><pub-id pub-id-type="pmcid">PMC6214657</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waks</surname><given-names>AG</given-names></name><name name-style="western"><surname>Winer</surname><given-names>EP</given-names></name></person-group><article-title>Breast Cancer treatment: A review</article-title><source>JAMA</source><year>2019</year><volume>321</volume><fpage>288</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.19323</pub-id><pub-id pub-id-type="pmid">30667505</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Waks AG, Winer EP. Breast Cancer treatment: A review. JAMA. 2019;321:288&#8211;300. 10.1001/jama.2018.19323.<pub-id pub-id-type="pmid">30667505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.19323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wildiers</surname><given-names>H</given-names></name><name name-style="western"><surname>Forceville</surname><given-names>K</given-names></name><name name-style="western"><surname>Paridaens</surname><given-names>R</given-names></name><name name-style="western"><surname>Joensuu</surname><given-names>H</given-names></name></person-group><article-title>Taxanes and anthracyclines in early breast cancer: which first?</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>219</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70025-5</pub-id><pub-id pub-id-type="pmid">20202604</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wildiers H, Forceville K, Paridaens R, Joensuu H. Taxanes and anthracyclines in early breast cancer: which first? Lancet Oncol. 2010;11:219&#8211;20. 10.1016/S1470-2045(10)70025-5.<pub-id pub-id-type="pmid">20202604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(10)70025-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreopoulou</surname><given-names>E</given-names></name><name name-style="western"><surname>Sparano</surname><given-names>JA</given-names></name></person-group><article-title>Chemotherapy in patients with anthracycline- and Taxane-Pretreated metastatic breast cancer: an overview, curr</article-title><source>Breast Cancer Rep</source><year>2013</year><volume>5</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s12609-012-0097-1</pub-id><pub-id pub-id-type="pmcid">PMC3579672</pub-id><pub-id pub-id-type="pmid">23440080</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Andreopoulou E, Sparano JA. Chemotherapy in patients with anthracycline- and Taxane-Pretreated metastatic breast cancer: an overview, curr. Breast Cancer Rep. 2013;5:42&#8211;50. 10.1007/s12609-012-0097-1.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12609-012-0097-1</pub-id><pub-id pub-id-type="pmcid">PMC3579672</pub-id><pub-id pub-id-type="pmid">23440080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sparano</surname><given-names>JA</given-names></name></person-group><article-title>Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials</article-title><source>Clin Breast Cancer</source><year>2000</year><volume>1</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.3816/CBC.2000.n.002</pub-id><pub-id pub-id-type="pmid">11899388</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1:32&#8211;40. 10.3816/CBC.2000.n.002. discussion 41&#8211;42.<pub-id pub-id-type="pmid">11899388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3816/CBC.2000.n.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>AN</given-names></name><name name-style="western"><surname>Gradishar</surname><given-names>WJ</given-names></name></person-group><article-title>Adjuvant anthracyclines in breast cancer: what is their role??</article-title><source>Oncologist</source><year>2018</year><volume>23</volume><fpage>1153</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2017-0672</pub-id><pub-id pub-id-type="pmid">30120159</pub-id><pub-id pub-id-type="pmcid">PMC6263120</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Shah AN, Gradishar WJ. Adjuvant anthracyclines in breast cancer: what is their role?? Oncologist. 2018;23:1153&#8211;61. 10.1634/theoncologist.2017-0672.<pub-id pub-id-type="pmid">30120159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2017-0672</pub-id><pub-id pub-id-type="pmcid">PMC6263120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><name name-style="western"><surname>Cho</surname><given-names>WC</given-names></name></person-group><article-title>Chemoresistance mechanisms of breast cancer and their countermeasures</article-title><source>Biomed Pharmacother</source><year>2019</year><volume>114</volume><fpage>108800</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.108800</pub-id><pub-id pub-id-type="pmid">30921705</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800. 10.1016/j.biopha.2019.108800.<pub-id pub-id-type="pmid">30921705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2019.108800</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Fang</surname><given-names>M</given-names></name></person-group><article-title>Chemoresistance and metastasis in breast Cancer molecular mechanisms and novel clinical strategies</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>1701</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.658552</pub-id><pub-id pub-id-type="pmcid">PMC8281885</pub-id><pub-id pub-id-type="pmid">34277408</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Cao J, Zhang M, Wang B, Zhang L, Zhou F, Fang M. Chemoresistance and metastasis in breast Cancer molecular mechanisms and novel clinical strategies. Front Oncol. 2021;11:1701. 10.3389/fonc.2021.658552.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.658552</pub-id><pub-id pub-id-type="pmcid">PMC8281885</pub-id><pub-id pub-id-type="pmid">34277408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">United Nations, THE 17 GOALS | Sustainable Development. 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sdgs.un.org/goals">https://sdgs.un.org/goals</ext-link>.&#160;Accessed May 20, 2025.</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansoori</surname><given-names>B</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Davudian</surname><given-names>S</given-names></name><name name-style="western"><surname>Shirjang</surname><given-names>S</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>B</given-names></name></person-group><article-title>The different mechanisms of Cancer drug resistance: A brief review</article-title><source>Adv Pharm Bull</source><year>2017</year><volume>7</volume><fpage>339</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.15171/apb.2017.041</pub-id><pub-id pub-id-type="pmid">29071215</pub-id><pub-id pub-id-type="pmcid">PMC5651054</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of Cancer drug resistance: A brief review. Adv Pharm Bull. 2017;7:339&#8211;48. 10.15171/apb.2017.041.<pub-id pub-id-type="pmid">29071215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15171/apb.2017.041</pub-id><pub-id pub-id-type="pmcid">PMC5651054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos</surname><given-names>A</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>S</given-names></name><name name-style="western"><surname>Tabatabaeian</surname><given-names>H</given-names></name></person-group><article-title>Battling chemoresistance in cancer: root causes and strategies to uproot them</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>9451</fpage><pub-id pub-id-type="doi">10.3390/ijms22179451</pub-id><pub-id pub-id-type="pmid">34502361</pub-id><pub-id pub-id-type="pmcid">PMC8430957</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Ramos A, Sadeghi S, Tabatabaeian H. Battling chemoresistance in cancer: root causes and strategies to uproot them. Int J Mol Sci. 2021;22:9451. 10.3390/ijms22179451.<pub-id pub-id-type="pmid">34502361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22179451</pub-id><pub-id pub-id-type="pmcid">PMC8430957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q</given-names></name></person-group><article-title>The role of centrosomal Nlp in the control of mitotic progression and tumourigenesis</article-title><source>Br J Cancer</source><year>2011</year><volume>104</volume><fpage>1523</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.130</pub-id><pub-id pub-id-type="pmid">21505454</pub-id><pub-id pub-id-type="pmcid">PMC3101908</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Li J, Zhan Q. The role of centrosomal Nlp in the control of mitotic progression and tumourigenesis. Br J Cancer. 2011;104:1523&#8211;8. 10.1038/bjc.2011.130.<pub-id pub-id-type="pmid">21505454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2011.130</pub-id><pub-id pub-id-type="pmcid">PMC3101908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q</given-names></name></person-group><article-title>Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to Paclitaxel</article-title><source>Cancer Biol Ther</source><year>2012</year><volume>13</volume><fpage>156</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.4161/cbt.13.3.18697</pub-id><pub-id pub-id-type="pmid">22353935</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhao W, Song Y, Xu B, Zhan Q. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to Paclitaxel. Cancer Biol Ther. 2012;13:156&#8211;63. 10.4161/cbt.13.3.18697.<pub-id pub-id-type="pmid">22353935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/cbt.13.3.18697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marina</surname><given-names>M</given-names></name><name name-style="western"><surname>Saavedra</surname><given-names>HI</given-names></name></person-group><article-title>Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance</article-title><source>Front Biosci Landmark Ed</source><year>2014</year><volume>19</volume><fpage>352</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.2741/4212</pub-id><pub-id pub-id-type="pmid">24389189</pub-id><pub-id pub-id-type="pmcid">PMC3999971</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Marina M, Saavedra HI. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci Landmark Ed. 2014;19:352&#8211;65. 10.2741/4212.<pub-id pub-id-type="pmid">24389189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2741/4212</pub-id><pub-id pub-id-type="pmcid">PMC3999971</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schatten</surname><given-names>H</given-names></name></person-group><article-title>The mammalian centrosome and its functional significance</article-title><source>Histochem Cell Biol</source><year>2008</year><volume>129</volume><fpage>667</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00418-008-0427-6</pub-id><pub-id pub-id-type="pmid">18437411</pub-id><pub-id pub-id-type="pmcid">PMC2386528</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Schatten H. The mammalian centrosome and its functional significance. Histochem Cell Biol. 2008;129:667&#8211;86. 10.1007/s00418-008-0427-6.<pub-id pub-id-type="pmid">18437411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00418-008-0427-6</pub-id><pub-id pub-id-type="pmcid">PMC2386528</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettencourt-Dias</surname><given-names>M</given-names></name><collab>Q&amp;A</collab></person-group><article-title>Who needs a centrosome?</article-title><source>BMC Biol</source><year>2013</year><volume>11</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/1741-7007-11-28</pub-id><pub-id pub-id-type="pmid">23578281</pub-id><pub-id pub-id-type="pmcid">PMC3623764</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Bettencourt-Dias M, Q&amp;A. Who needs a centrosome? BMC Biol. 2013;11:28. 10.1186/1741-7007-11-28.<pub-id pub-id-type="pmid">23578281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1741-7007-11-28</pub-id><pub-id pub-id-type="pmcid">PMC3623764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazockdast</surname><given-names>E</given-names></name><name name-style="western"><surname>Redemann</surname><given-names>S</given-names></name></person-group><article-title>Mechanics of the spindle apparatus, Semin</article-title><source>Cell Dev Biol</source><year>2020</year><volume>107</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2020.06.018</pub-id><pub-id pub-id-type="pmid">32747191</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Nazockdast E, Redemann S. Mechanics of the spindle apparatus, Semin. Cell Dev Biol. 2020;107:91&#8211;102. 10.1016/j.semcdb.2020.06.018.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcdb.2020.06.018</pub-id><pub-id pub-id-type="pmid">32747191</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Wu Q, Li B, Liu L, Sun S, Sun S. Centrosome dysfunction: a link between senescence and tumor immunity, signal transduct. Target Ther. 2020;5. 10.1038/s41392-020-00214-7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00214-7</pub-id><pub-id pub-id-type="pmcid">PMC7327052</pub-id><pub-id pub-id-type="pmid">32606370</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Fu J, Hagan IM, Glover DM. The centrosome and its duplication cycle, cold spring Harb. Perspect Biol. 2015;7. 10.1101/cshperspect.a015800.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a015800</pub-id><pub-id pub-id-type="pmcid">PMC4315929</pub-id><pub-id pub-id-type="pmid">25646378</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kr&#228;mer</surname><given-names>A</given-names></name><name name-style="western"><surname>Neben</surname><given-names>K</given-names></name><name name-style="western"><surname>Ho</surname><given-names>AD</given-names></name></person-group><article-title>Centrosome replication, genomic instability and cancer</article-title><source>Leukemia</source><year>2002</year><volume>16</volume><fpage>767</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2402454</pub-id><pub-id pub-id-type="pmid">11986936</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kr&#228;mer A, Neben K, Ho AD. Centrosome replication, genomic instability and cancer. Leukemia. 2002;16:767&#8211;75. 10.1038/sj.leu.2402454.<pub-id pub-id-type="pmid">11986936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.leu.2402454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Jusino S, Fern&#225;ndez-Pad&#237;n FM, Saavedra HI. Centrosome aberrations and chromosome instability contribute to tumorigenesis and intra-tumor heterogeneity. J Cancer Metastasis Treat. 2018;4. 10.20517/2394-4722.2018.24.<pub-id pub-id-type="doi" assigning-authority="pmc">10.20517/2394-4722.2018.24</pub-id><pub-id pub-id-type="pmcid">PMC6205736</pub-id><pub-id pub-id-type="pmid">30381801</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lingle</surname><given-names>WL</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>WH</given-names></name><name name-style="western"><surname>Ingle</surname><given-names>JN</given-names></name><name name-style="western"><surname>Maihle</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Salisbury</surname><given-names>JL</given-names></name></person-group><article-title>Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell Polarity</article-title><source>Proc Natl Acad Sci</source><year>1998</year><volume>95</volume><fpage>2950</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.6.2950</pub-id><pub-id pub-id-type="pmid">9501196</pub-id><pub-id pub-id-type="pmcid">PMC19675</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell Polarity. Proc Natl Acad Sci. 1998;95:2950&#8211;5. 10.1073/pnas.95.6.2950.<pub-id pub-id-type="pmid">9501196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.95.6.2950</pub-id><pub-id pub-id-type="pmcid">PMC19675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhakta-Guha</surname><given-names>D</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>MEM</given-names></name><name name-style="western"><surname>Greten</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Efferth</surname><given-names>T</given-names></name></person-group><article-title>Dis-organizing centrosomal clusters: specific cancer therapy for a generic spread?</article-title><source>Curr Med Chem</source><year>2015</year><volume>22</volume><fpage>685</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.2174/0929867322666141212114529</pub-id><pub-id pub-id-type="pmid">25515519</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Bhakta-Guha D, Saeed MEM, Greten HJ, Efferth T. Dis-organizing centrosomal clusters: specific cancer therapy for a generic spread? Curr Med Chem. 2015;22:685&#8211;94. 10.2174/0929867322666141212114529.<pub-id pub-id-type="pmid">25515519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867322666141212114529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogden</surname><given-names>A</given-names></name><name name-style="western"><surname>Rida</surname><given-names>PCG</given-names></name><name name-style="western"><surname>Aneja</surname><given-names>R</given-names></name></person-group><article-title>Centrosome amplification: a suspect in breast cancer and Racial disparities</article-title><source>Endocr Relat Cancer</source><year>2017</year><volume>24</volume><fpage>T47</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1530/ERC-17-0072</pub-id><pub-id pub-id-type="pmid">28515047</pub-id><pub-id pub-id-type="pmcid">PMC5837860</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ogden A, Rida PCG, Aneja R. Centrosome amplification: a suspect in breast cancer and Racial disparities. Endocr Relat Cancer. 2017;24:T47&#8211;64. 10.1530/ERC-17-0072.<pub-id pub-id-type="pmid">28515047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/ERC-17-0072</pub-id><pub-id pub-id-type="pmcid">PMC5837860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priyanga</surname><given-names>J</given-names></name><name name-style="western"><surname>Guha</surname><given-names>G</given-names></name><name name-style="western"><surname>Bhakta-Guha</surname><given-names>D</given-names></name></person-group><article-title>Microtubule motors in centrosome homeostasis: A target for cancer therapy?</article-title><source>Biochim Biophys Acta Rev Cancer</source><year>2021</year><volume>1875</volume><fpage>188524</fpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2021.188524</pub-id><pub-id pub-id-type="pmid">33582170</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Priyanga J, Guha G, Bhakta-Guha D. Microtubule motors in centrosome homeostasis: A target for cancer therapy? Biochim Biophys Acta Rev Cancer. 2021;1875:188524. 10.1016/j.bbcan.2021.188524.<pub-id pub-id-type="pmid">33582170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2021.188524</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P, Motors M. Mol. Biol. Cell 4th Ed. 2002. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK26888/">https://www.ncbi.nlm.nih.gov/books/NBK26888/</ext-link>.&#160;Accessed 22 Apr 2020.</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Cooper GM. Microtubule Motors and Movements, Cell Mol. Approach 2nd Ed. 2000. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK9833/">https://www.ncbi.nlm.nih.gov/books/NBK9833/</ext-link>. Accessed 22 Apr 2020.</mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Kinesin, Dynein, and Intracellular Transport, in: Mol. Cell Biol., 4th ed., W. H. Freeman, 2000. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK21710/">https://www.ncbi.nlm.nih.gov/books/NBK21710/</ext-link>.&#160;Accessed 20 Apr 2020.</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallik</surname><given-names>R</given-names></name><name name-style="western"><surname>Rai</surname><given-names>AK</given-names></name><name name-style="western"><surname>Barak</surname><given-names>P</given-names></name><name name-style="western"><surname>Rai</surname><given-names>A</given-names></name><name name-style="western"><surname>Kunwar</surname><given-names>A</given-names></name></person-group><article-title>Teamwork in microtubule motors</article-title><source>Trends Cell Biol</source><year>2013</year><volume>23</volume><fpage>575</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2013.06.003</pub-id><pub-id pub-id-type="pmid">23877011</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Mallik R, Rai AK, Barak P, Rai A, Kunwar A. Teamwork in microtubule motors. Trends Cell Biol. 2013;23:575&#8211;82. 10.1016/j.tcb.2013.06.003.<pub-id pub-id-type="pmid">23877011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2013.06.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huo</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J-D</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J</given-names></name></person-group><article-title>Roles of Kinesin superfamily proteins in colorectal cancer carcinogenesis (Review)</article-title><source>Oncol Rep</source><year>2021</year><volume>46</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3892/or.2021.8072</pub-id><pub-id pub-id-type="pmid">33955521</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Huo D, Yang H, Huang J-D, Cai J-P, Cui J. Roles of Kinesin superfamily proteins in colorectal cancer carcinogenesis (Review). Oncol Rep. 2021;46:1&#8211;10. 10.3892/or.2021.8072.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2021.8072</pub-id><pub-id pub-id-type="pmid">33955521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q-H</given-names></name></person-group><article-title>Crosstalk between microtubule stabilizing agents and prostate Cancer</article-title><source>Cancers</source><year>2023</year><volume>15</volume><fpage>3308</fpage><pub-id pub-id-type="doi">10.3390/cancers15133308</pub-id><pub-id pub-id-type="pmid">37444418</pub-id><pub-id pub-id-type="pmcid">PMC10340777</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Chen Q-H. Crosstalk between microtubule stabilizing agents and prostate Cancer. Cancers. 2023;15:3308. 10.3390/cancers15133308.<pub-id pub-id-type="pmid">37444418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15133308</pub-id><pub-id pub-id-type="pmcid">PMC10340777</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Liu X, Lin Y, Long W, Yi R, Zhang X, Xie C, Jin N, Qiu Z, Liu X. The kinesin-14 family motor protein KIFC2 promotes prostate cancer progression by regulating p65. J Biol Chem. 2023;299. 10.1016/j.jbc.2023.105253.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2023.105253</pub-id><pub-id pub-id-type="pmcid">PMC10590982</pub-id><pub-id pub-id-type="pmid">37716704</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name></person-group><article-title>Kinesin KIF4A is associated with chemotherapeutic drug resistance by regulating intracellular trafficking of lung resistance-related protein</article-title><source>J Zhejiang Univ Sci B</source><year>2017</year><volume>18</volume><fpage>1046</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1631/jzus.B1700129</pub-id><pub-id pub-id-type="pmid">29204984</pub-id><pub-id pub-id-type="pmcid">PMC5742287</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Pan L, Zhang Y, Zhu C, Dong Z. Kinesin KIF4A is associated with chemotherapeutic drug resistance by regulating intracellular trafficking of lung resistance-related protein. J Zhejiang Univ Sci B. 2017;18:1046&#8211;54. 10.1631/jzus.B1700129.<pub-id pub-id-type="pmid">29204984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1631/jzus.B1700129</pub-id><pub-id pub-id-type="pmcid">PMC5742287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yukuyama</surname><given-names>MN</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>A</given-names></name><name name-style="western"><surname>Henostroza</surname><given-names>MAB</given-names></name><name name-style="western"><surname>de Araujo</surname><given-names>GLB</given-names></name><name name-style="western"><surname>L&#246;benberg</surname><given-names>R</given-names></name><name name-style="western"><surname>de Faria</surname><given-names>R</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>GB</given-names></name><name name-style="western"><surname>Guimaraes</surname><given-names>LMF</given-names></name><name name-style="western"><surname>Lameu</surname><given-names>C</given-names></name><name name-style="western"><surname>Folchini</surname><given-names>BR</given-names></name><name name-style="western"><surname>Peroni</surname><given-names>CM</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>IF</given-names></name><name name-style="western"><surname>Miyagi</surname><given-names>MYS</given-names></name></person-group><article-title>Bou-Chacra, unveiling microtubule dynamics in lung cancer: recent findings and prospects for drug delivery and treatment</article-title><source>J Drug Deliv Sci Technol</source><year>2023</year><volume>89</volume><fpage>105017</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2023.105017</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Yukuyama MN, de Souza A, Henostroza MAB, de Araujo GLB, L&#246;benberg R, de Faria R, de Souza GB, Guimaraes LMF, Lameu C, Folchini BR, Peroni CM, Oliveira IF, Miyagi MYS. Bou-Chacra, unveiling microtubule dynamics in lung cancer: recent findings and prospects for drug delivery and treatment. J Drug Deliv Sci Technol. 2023;89:105017. 10.1016/j.jddst.2023.105017.</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W</given-names></name></person-group><article-title>The role of Kinesin family members in hepatobiliary carcinomas: from bench to bedside</article-title><source>Biomark Res</source><year>2024</year><volume>12</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/s40364-024-00559-z</pub-id><pub-id pub-id-type="pmid">38433242</pub-id><pub-id pub-id-type="pmcid">PMC10910842</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Zhao K, Li X, Feng Y, Wang J, Yao W. The role of Kinesin family members in hepatobiliary carcinomas: from bench to bedside. Biomark Res. 2024;12:30. 10.1186/s40364-024-00559-z.<pub-id pub-id-type="pmid">38433242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-024-00559-z</pub-id><pub-id pub-id-type="pmcid">PMC10910842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De</surname><given-names>S</given-names></name><name name-style="western"><surname>Cipriano</surname><given-names>R</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>MW</given-names></name><name name-style="western"><surname>Stark</surname><given-names>GR</given-names></name></person-group><article-title>Overexpression of kinesins mediates docetaxel resistance in breast Cancer cells</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>8035</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1224</pub-id><pub-id pub-id-type="pmid">19789344</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">De S, Cipriano R, Jackson MW, Stark GR. Overexpression of kinesins mediates docetaxel resistance in breast Cancer cells. Cancer Res. 2009;69:8035&#8211;42.<pub-id pub-id-type="pmid">19789344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-09-1224</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>MH</given-names></name><name name-style="western"><surname>De</surname><given-names>S</given-names></name><name name-style="western"><surname>Bebek</surname><given-names>G</given-names></name><name name-style="western"><surname>Orloff</surname><given-names>MS</given-names></name><name name-style="western"><surname>Wesolowski</surname><given-names>R</given-names></name><name name-style="western"><surname>Downs-Kelly</surname><given-names>E</given-names></name><name name-style="western"><surname>Budd</surname><given-names>GT</given-names></name><name name-style="western"><surname>Stark</surname><given-names>GR</given-names></name><name name-style="western"><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Specific Kinesin expression profiles associated with taxane resistance in basal-like breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2012</year><volume>131</volume><fpage>849</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s10549-011-1500-8</pub-id><pub-id pub-id-type="pmid">21479552</pub-id><pub-id pub-id-type="pmcid">PMC4038085</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, Budd GT, Stark GR, Eng C. Specific Kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat. 2012;131:849&#8211;58. 10.1007/s10549-011-1500-8.<pub-id pub-id-type="pmid">21479552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-011-1500-8</pub-id><pub-id pub-id-type="pmcid">PMC4038085</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singel</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cornelius</surname><given-names>C</given-names></name><name name-style="western"><surname>Zaganjor</surname><given-names>E</given-names></name><name name-style="western"><surname>Batten</surname><given-names>K</given-names></name><name name-style="western"><surname>Sarode</surname><given-names>VR</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>DL</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>John</surname><given-names>GB</given-names></name><name name-style="western"><surname>Li</surname><given-names>HC</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>N</given-names></name><name name-style="western"><surname>Wright</surname><given-names>WE</given-names></name><name name-style="western"><surname>Lum</surname><given-names>L</given-names></name><name name-style="western"><surname>Corson</surname><given-names>TW</given-names></name><name name-style="western"><surname>Shay</surname><given-names>JW</given-names></name></person-group><article-title>KIF14 promotes AKT phosphorylation and contributes to chemoresistance in Triple-Negative breast cancer, neoplasia N</article-title><source>Y N</source><year>2014</year><volume>16</volume><fpage>247</fpage><lpage>e2562</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2014.03.008</pub-id><pub-id pub-id-type="pmcid">PMC4094827</pub-id><pub-id pub-id-type="pmid">24784001</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, Peng Y, John GB, Li HC, Sadeghi N, Wright WE, Lum L, Corson TW, Shay JW. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in Triple-Negative breast cancer, neoplasia N. Y N. 2014;16:247&#8211;e2562. 10.1016/j.neo.2014.03.008.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2014.03.008</pub-id><pub-id pub-id-type="pmcid">PMC4094827</pub-id><pub-id pub-id-type="pmid">24784001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Agircan FG, Schiebel E, Mardin BR. Separate to operate: control of centrosome positioning and separation. Philos Trans R Soc B Biol Sci. 2014;369. 10.1098/rstb.2013.0461.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rstb.2013.0461</pub-id><pub-id pub-id-type="pmcid">PMC4113105</pub-id><pub-id pub-id-type="pmid">25047615</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>CG</given-names></name></person-group><article-title>KIFC3 directs a centrosome cohesive force</article-title><source>Nat Cell Biol</source><year>2019</year><volume>21</volume><fpage>1057</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0385-3</pub-id><pub-id pub-id-type="pmid">31481794</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Morrison CG. KIFC3 directs a centrosome cohesive force. Nat Cell Biol. 2019;21:1057&#8211;9. 10.1038/s41556-019-0385-3.<pub-id pub-id-type="pmid">31481794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-019-0385-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parvin</surname><given-names>A</given-names></name><name name-style="western"><surname>Hao</surname><given-names>S-L</given-names></name><name name-style="western"><surname>Tan</surname><given-names>F-Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W-X</given-names></name></person-group><article-title>Inhibition of Kinesin motor protein KIFC1 by AZ82 induces multipolar mitosis and apoptosis in prostate cancer cell</article-title><source>Gene</source><year>2020</year><volume>760</volume><fpage>144989</fpage><pub-id pub-id-type="doi">10.1016/j.gene.2020.144989</pub-id><pub-id pub-id-type="pmid">32717307</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Parvin A, Hao S-L, Tan F-Q, Yang W-X. Inhibition of Kinesin motor protein KIFC1 by AZ82 induces multipolar mitosis and apoptosis in prostate cancer cell. Gene. 2020;760:144989. 10.1016/j.gene.2020.144989.<pub-id pub-id-type="pmid">32717307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gene.2020.144989</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title>The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-20208-x</pub-id><pub-id pub-id-type="pmid">33397932</pub-id><pub-id pub-id-type="pmcid">PMC7782532</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Fan G, Sun L, Meng L, Hu C, Wang X, Shi Z, Hu C, Han Y, Yang Q, Cao L, Zhang X, Zhang Y, Song X, Xia S, He B, Zhang S, Wang C. The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation. Nat Commun. 2021;12:20. 10.1038/s41467-020-20208-x.<pub-id pub-id-type="pmid">33397932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-20208-x</pub-id><pub-id pub-id-type="pmcid">PMC7782532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>CD</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>JM</given-names></name><name name-style="western"><surname>Akl</surname><given-names>EA</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>SE</given-names></name><name name-style="western"><surname>Chou</surname><given-names>R</given-names></name><name name-style="western"><surname>Glanville</surname><given-names>J</given-names></name><name name-style="western"><surname>Grimshaw</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hr&#243;bjartsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Lalu</surname><given-names>MM</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Loder</surname><given-names>EW</given-names></name><name name-style="western"><surname>Mayo-Wilson</surname><given-names>E</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>S</given-names></name><name name-style="western"><surname>McGuinness</surname><given-names>LA</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>LA</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J</given-names></name><name name-style="western"><surname>Tricco</surname><given-names>AC</given-names></name><name name-style="western"><surname>Welch</surname><given-names>VA</given-names></name><name name-style="western"><surname>Whiting</surname><given-names>P</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#243;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 10.1136/bmj.n71.<pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">PRISMA, flow chart PRISMA. 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://prisma-statement.org/prismastatement/flowdiagram.aspx">http://prisma-statement.org/prismastatement/flowdiagram.aspx</ext-link>. Accessed 23 Nov 2021.</mixed-citation></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>GZ</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J</given-names></name><name name-style="western"><surname>Hermanto</surname><given-names>U</given-names></name><name name-style="western"><surname>Zong</surname><given-names>CS</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L-H</given-names></name></person-group><article-title>RACK1 and CIS mediate the degradation of BimEL in Cancer cells</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>16416</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1074/jbc.M802360200</pub-id><pub-id pub-id-type="pmid">18420585</pub-id><pub-id pub-id-type="pmcid">PMC2423247</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Zhang W, Cheng GZ, Gong J, Hermanto U, Zong CS, Chan J, Cheng JQ, Wang L-H. RACK1 and CIS mediate the degradation of BimEL in Cancer cells. J Biol Chem. 2008;283:16416&#8211;26. 10.1074/jbc.M802360200.<pub-id pub-id-type="pmid">18420585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M802360200</pub-id><pub-id pub-id-type="pmcid">PMC2423247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues-Ferreira</surname><given-names>S</given-names></name><name name-style="western"><surname>Nehlig</surname><given-names>A</given-names></name><name name-style="western"><surname>Moindjie</surname><given-names>H</given-names></name><name name-style="western"><surname>Monchecourt</surname><given-names>C</given-names></name><name name-style="western"><surname>Seiler</surname><given-names>C</given-names></name><name name-style="western"><surname>Marangoni</surname><given-names>E</given-names></name><name name-style="western"><surname>Chateau-Joubert</surname><given-names>S</given-names></name><name name-style="western"><surname>Dujaric</surname><given-names>M-E</given-names></name><name name-style="western"><surname>Servant</surname><given-names>N</given-names></name><name name-style="western"><surname>Asselain</surname><given-names>B</given-names></name><name name-style="western"><surname>de Cremoux</surname><given-names>P</given-names></name><name name-style="western"><surname>Lacroix-Triki</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnedos</surname><given-names>M</given-names></name><name name-style="western"><surname>Pierga</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>F</given-names></name><name name-style="western"><surname>Nahmias</surname><given-names>C</given-names></name></person-group><article-title>Improving breast cancer sensitivity to Paclitaxel by increasing aneuploidy</article-title><source>Proc Natl Acad Sci</source><year>2019</year><volume>116</volume><fpage>23691</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.1910824116</pub-id><pub-id pub-id-type="pmid">31685623</pub-id><pub-id pub-id-type="pmcid">PMC6876190</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Rodrigues-Ferreira S, Nehlig A, Moindjie H, Monchecourt C, Seiler C, Marangoni E, Chateau-Joubert S, Dujaric M-E, Servant N, Asselain B, de Cremoux P, Lacroix-Triki M, Arnedos M, Pierga J-Y, Andr&#233; F, Nahmias C. Improving breast cancer sensitivity to Paclitaxel by increasing aneuploidy. Proc Natl Acad Sci. 2019;116:23691&#8211;7. 10.1073/pnas.1910824116.<pub-id pub-id-type="pmid">31685623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1910824116</pub-id><pub-id pub-id-type="pmcid">PMC6876190</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>VC</given-names></name></person-group><article-title>The role of Tamoxifen in the treatment and prevention of breast cancer</article-title><source>Curr Probl Cancer</source><year>1992</year><volume>16</volume><fpage>129</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/0147-0272(92)90002-6</pub-id><pub-id pub-id-type="pmid">1582240</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Jordan VC. The role of Tamoxifen in the treatment and prevention of breast cancer. Curr Probl Cancer. 1992;16:129&#8211;76. 10.1016/0147-0272(92)90002-6.<pub-id pub-id-type="pmid">1582240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0147-0272(92)90002-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binkhorst</surname><given-names>L</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>RHJ</given-names></name></person-group><article-title>Individualization of Tamoxifen treatment for breast carcinoma</article-title><source>Clin Pharmacol Ther</source><year>2012</year><volume>92</volume><fpage>431</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/clpt.2012.94</pub-id><pub-id pub-id-type="pmid">22910442</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Binkhorst L, van Gelder T, Mathijssen RHJ. Individualization of Tamoxifen treatment for breast carcinoma. Clin Pharmacol Ther. 2012;92:431&#8211;3. 10.1038/clpt.2012.94.<pub-id pub-id-type="pmid">22910442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2012.94</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>R</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>A</given-names></name><name name-style="western"><surname>Jing</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of twist via PI3K/AKT/NF-&#954;B signaling</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>9575</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-27810-6</pub-id><pub-id pub-id-type="pmid">29934505</pub-id><pub-id pub-id-type="pmcid">PMC6015029</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Han R, Gu S, Zhang Y, Luo A, Jing X, Zhao L, Zhao X, Zhang L. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of twist via PI3K/AKT/NF-&#954;B signaling. Sci Rep. 2018;8:9575. 10.1038/s41598-018-27810-6.<pub-id pub-id-type="pmid">29934505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-27810-6</pub-id><pub-id pub-id-type="pmcid">PMC6015029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Farrar MC, Jacobs TF. Tamoxifen, in: StatPearls, StatPearls Publishing, Treasure Island (FL), 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK532905/">http://www.ncbi.nlm.nih.gov/books/NBK532905/</ext-link>.&#160;Accessed 12 Nov 2021.</mixed-citation></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>S</given-names></name><name name-style="western"><surname>Rasool</surname><given-names>M</given-names></name><name name-style="western"><surname>Chaoudhry</surname><given-names>H</given-names></name><name name-style="western"><surname>Pushparaj</surname><given-names>PN</given-names></name><name name-style="western"><surname>Jha</surname><given-names>P</given-names></name><name name-style="western"><surname>Hafiz</surname><given-names>A</given-names></name><name name-style="western"><surname>Mahfooz</surname><given-names>M</given-names></name><name name-style="western"><surname>Abdus Sami</surname><given-names>G</given-names></name><name name-style="western"><surname>Azhar Kamal</surname><given-names>M</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>S</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A</given-names></name></person-group><article-title>Sarwar jamal, molecular mechanisms and mode of Tamoxifen resistance in breast cancer</article-title><source>Bioinformation</source><year>2016</year><volume>12</volume><fpage>135</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.6026/97320630012135</pub-id><pub-id pub-id-type="pmid">28149048</pub-id><pub-id pub-id-type="pmcid">PMC5267957</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Ali S, Rasool M, Chaoudhry H, Pushparaj PN, Jha P, Hafiz A, Mahfooz M, Abdus Sami G, Azhar Kamal M, Bashir S, Ali A. Sarwar jamal, molecular mechanisms and mode of Tamoxifen resistance in breast cancer. Bioinformation. 2016;12:135&#8211;9. 10.6026/97320630012135.<pub-id pub-id-type="pmid">28149048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6026/97320630012135</pub-id><pub-id pub-id-type="pmcid">PMC5267957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>JX</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Sokolov</surname><given-names>A</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CZ</given-names></name><name name-style="western"><surname>Li</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H-W</given-names></name></person-group><article-title>Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and Tamoxifen resistance</article-title><source>Mol Cancer Res MCR</source><year>2014</year><volume>12</volume><fpage>539</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0459</pub-id><pub-id pub-id-type="pmid">24391143</pub-id><pub-id pub-id-type="pmcid">PMC4139106</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Zou JX, Duan Z, Wang J, Sokolov A, Xu J, Chen CZ, Li JJ, Chen H-W. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and Tamoxifen resistance. Mol Cancer Res MCR. 2014;12:539&#8211;49. 10.1158/1541-7786.MCR-13-0459.<pub-id pub-id-type="pmid">24391143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1541-7786.MCR-13-0459</pub-id><pub-id pub-id-type="pmcid">PMC4139106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>JX</given-names></name><name name-style="western"><surname>Revenko</surname><given-names>AS</given-names></name><name name-style="western"><surname>Li</surname><given-names>LB</given-names></name><name name-style="western"><surname>Gemo</surname><given-names>AT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H-W</given-names></name></person-group><article-title>ANCCA, an estrogen-regulated AAA&#8201;+&#8201;ATPase coactivator for ER&#945;, is required for coregulator occupancy and chromatin modification</article-title><source>Proc Natl Acad Sci</source><year>2007</year><volume>104</volume><fpage>18067</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705814104</pub-id><pub-id pub-id-type="pmid">17998543</pub-id><pub-id pub-id-type="pmcid">PMC2084297</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Zou JX, Revenko AS, Li LB, Gemo AT, Chen H-W. ANCCA, an estrogen-regulated AAA&#8201;+&#8201;ATPase coactivator for ER&#945;, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci. 2007;104:18067&#8211;72. 10.1073/pnas.0705814104.<pub-id pub-id-type="pmid">17998543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0705814104</pub-id><pub-id pub-id-type="pmcid">PMC2084297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfarsi</surname><given-names>LH</given-names></name><name name-style="western"><surname>Elansari</surname><given-names>R</given-names></name><name name-style="western"><surname>Toss</surname><given-names>MS</given-names></name><name name-style="western"><surname>Diez-Rodriguez</surname><given-names>M</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>CC</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>IO</given-names></name><name name-style="western"><surname>Rakha</surname><given-names>EA</given-names></name><name name-style="western"><surname>Green</surname><given-names>AR</given-names></name></person-group><article-title>Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER&#8201;+&#8201;breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2019</year><volume>173</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1007/s10549-018-4978-5</pub-id><pub-id pub-id-type="pmid">30306428</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Alfarsi LH, Elansari R, Toss MS, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER&#8201;+&#8201;breast cancer. Breast Cancer Res Treat. 2019;173:93&#8211;102. 10.1007/s10549-018-4978-5.<pub-id pub-id-type="pmid">30306428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-018-4978-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Johnson-Arbor K, Dubey R. Doxorubicin, in: StatPearls, StatPearls Publishing, Treasure Island (FL), 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK459232/">http://www.ncbi.nlm.nih.gov/books/NBK459232/</ext-link>. Accessed 13 Nov 2021.</mixed-citation></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christowitz</surname><given-names>C</given-names></name><name name-style="western"><surname>Davis</surname><given-names>T</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>A</given-names></name><name name-style="western"><surname>van Niekerk</surname><given-names>G</given-names></name><name name-style="western"><surname>Hattingh</surname><given-names>S</given-names></name><name name-style="western"><surname>Engelbrecht</surname><given-names>A-M</given-names></name></person-group><article-title>Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><fpage>757</fpage><pub-id pub-id-type="doi">10.1186/s12885-019-5939-z</pub-id><pub-id pub-id-type="pmid">31370818</pub-id><pub-id pub-id-type="pmcid">PMC6670209</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Christowitz C, Davis T, Isaacs A, van Niekerk G, Hattingh S, Engelbrecht A-M. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer. 2019;19:757. 10.1186/s12885-019-5939-z.<pub-id pub-id-type="pmid">31370818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-019-5939-z</pub-id><pub-id pub-id-type="pmcid">PMC6670209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title>Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial&#8208;mesenchymal transition</article-title><source>Cancer Sci</source><year>2020</year><volume>111</volume><fpage>1422</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/cas.14324</pub-id><pub-id pub-id-type="pmid">32011034</pub-id><pub-id pub-id-type="pmcid">PMC7156822</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Wang W, Zhang R, Wang X, Wang N, Zhao J, Wei Z, Xiang F, Wang C. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial&#8208;mesenchymal transition. Cancer Sci. 2020;111:1422&#8211;34. 10.1111/cas.14324.<pub-id pub-id-type="pmid">32011034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.14324</pub-id><pub-id pub-id-type="pmcid">PMC7156822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>C-F</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y-X</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y-C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L-Z</given-names></name><name name-style="western"><surname>Shu</surname><given-names>Y-Q</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X-M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B-H</given-names></name></person-group><article-title>TBX15/miR-152/KIF2C pathway regulates breast cancer doxorubicin resistance via promoting PKM2 ubiquitination</article-title><source>Cancer Cell Int</source><year>2021</year><volume>21</volume><fpage>542</fpage><pub-id pub-id-type="doi">10.1186/s12935-021-02235-w</pub-id><pub-id pub-id-type="pmid">34663310</pub-id><pub-id pub-id-type="pmcid">PMC8522147</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Jiang C-F, Xie Y-X, Qian Y-C, Wang M, Liu L-Z, Shu Y-Q, Bai X-M, Jiang B-H. TBX15/miR-152/KIF2C pathway regulates breast cancer doxorubicin resistance via promoting PKM2 ubiquitination. Cancer Cell Int. 2021;21:542. 10.1186/s12935-021-02235-w.<pub-id pub-id-type="pmid">34663310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-021-02235-w</pub-id><pub-id pub-id-type="pmcid">PMC8522147</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wilson</surname></name></person-group><article-title>Microtubules as a target for anticancer drugs</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>253</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nrc1317</pub-id><pub-id pub-id-type="pmid">15057285</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Jordan MA, Wilson. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253&#8211;65. 10.1038/nrc1317.<pub-id pub-id-type="pmid">15057285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maloney</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>CA</given-names></name><name name-style="western"><surname>Morejon-Lasso</surname><given-names>LV</given-names></name><name name-style="western"><surname>Prosperi</surname><given-names>JR</given-names></name></person-group><article-title>Mechanisms of taxane resistance</article-title><source>Cancers</source><year>2020</year><volume>12</volume><fpage>E3323</fpage><pub-id pub-id-type="doi">10.3390/cancers12113323</pub-id><pub-id pub-id-type="pmcid">PMC7697134</pub-id><pub-id pub-id-type="pmid">33182737</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of taxane resistance. Cancers. 2020;12:E3323. 10.3390/cancers12113323.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12113323</pub-id><pub-id pub-id-type="pmcid">PMC7697134</pub-id><pub-id pub-id-type="pmid">33182737</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahba</surname><given-names>HA</given-names></name><name name-style="western"><surname>El-Hadaad</surname><given-names>HA</given-names></name></person-group><article-title>Current approaches in treatment of triple-negative breast cancer</article-title><source>Cancer Biol Med</source><year>2015</year><volume>12</volume><fpage>106</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">26175926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7497/j.issn.2095-3941.2015.0030</pub-id><pub-id pub-id-type="pmcid">PMC4493381</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106&#8211;16.<pub-id pub-id-type="pmid">26175926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7497/j.issn.2095-3941.2015.0030</pub-id><pub-id pub-id-type="pmcid">PMC4493381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mustacchi</surname><given-names>G</given-names></name><name name-style="western"><surname>De Laurentiis</surname><given-names>M</given-names></name></person-group><article-title>The role of taxanes in triple-negative breast cancer: literature review</article-title><source>Drug Des Devel Ther</source><year>2015</year><volume>9</volume><fpage>4303</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S86105</pub-id><pub-id pub-id-type="pmid">26273192</pub-id><pub-id pub-id-type="pmcid">PMC4532347</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Mustacchi G, De Laurentiis M. The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther. 2015;9:4303&#8211;18. 10.2147/DDDT.S86105.<pub-id pub-id-type="pmid">26273192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S86105</pub-id><pub-id pub-id-type="pmcid">PMC4532347</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orr</surname><given-names>GA</given-names></name><name name-style="western"><surname>Verdier-Pinard</surname><given-names>P</given-names></name><name name-style="western"><surname>McDaid</surname><given-names>H</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>SB</given-names></name></person-group><article-title>Mechanisms of taxol resistance related to microtubules</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>7280</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206934</pub-id><pub-id pub-id-type="pmid">14576838</pub-id><pub-id pub-id-type="pmcid">PMC4039039</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene. 2003;22:7280&#8211;95. 10.1038/sj.onc.1206934.<pub-id pub-id-type="pmid">14576838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1206934</pub-id><pub-id pub-id-type="pmcid">PMC4039039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Froidevaux-Klipfel</surname><given-names>L</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>F</given-names></name><name name-style="western"><surname>Boursier</surname><given-names>C</given-names></name><name name-style="western"><surname>Cr&#233;pin</surname><given-names>R</given-names></name><name name-style="western"><surname>Po&#252;s</surname><given-names>C</given-names></name><name name-style="western"><surname>Baudin</surname><given-names>B</given-names></name><name name-style="western"><surname>Baillet</surname><given-names>A</given-names></name></person-group><article-title>Modulation of Septin and molecular motor recruitment in the microtubule environment of the Taxol-resistant human breast cancer cell line MDA-MB-231</article-title><source>Proteomics</source><year>2011</year><volume>11</volume><fpage>3877</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/pmic.201000789</pub-id><pub-id pub-id-type="pmid">21761557</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Froidevaux-Klipfel L, Poirier F, Boursier C, Cr&#233;pin R, Po&#252;s C, Baudin B, Baillet A. Modulation of Septin and molecular motor recruitment in the microtubule environment of the Taxol-resistant human breast cancer cell line MDA-MB-231. Proteomics. 2011;11:3877&#8211;86. 10.1002/pmic.201000789.<pub-id pub-id-type="pmid">21761557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pmic.201000789</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Ji</surname><given-names>HW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HW</given-names></name><name name-style="western"><surname>Yun</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>EH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name></person-group><article-title>Cold atmospheric plasma restores Paclitaxel sensitivity to Paclitaxel-Resistant breast Cancer cells by reversing expression of Resistance-Related genes</article-title><source>Cancers</source><year>2019</year><volume>11</volume><fpage>2011</fpage><pub-id pub-id-type="doi">10.3390/cancers11122011</pub-id><pub-id pub-id-type="pmid">31847101</pub-id><pub-id pub-id-type="pmcid">PMC6966695</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Park S, Kim H, Ji HW, Kim HW, Yun SH, Choi EH, Kim SJ. Cold atmospheric plasma restores Paclitaxel sensitivity to Paclitaxel-Resistant breast Cancer cells by reversing expression of Resistance-Related genes. Cancers. 2019;11:2011. 10.3390/cancers11122011.<pub-id pub-id-type="pmid">31847101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11122011</pub-id><pub-id pub-id-type="pmcid">PMC6966695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khongkow</surname><given-names>P</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>AR</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C</given-names></name><name name-style="western"><surname>Man</surname><given-names>EPS</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>JW-H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Coombes</surname><given-names>RC</given-names></name><name name-style="western"><surname>Medema</surname><given-names>RH</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>US</given-names></name></person-group><article-title>Lam, Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer Paclitaxel resistance</article-title><source>Oncogene</source><year>2016</year><volume>35</volume><fpage>990</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.152</pub-id><pub-id pub-id-type="pmid">25961928</pub-id><pub-id pub-id-type="pmcid">PMC4538879</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Khongkow P, Gomes AR, Gong C, Man EPS, Tsang JW-H, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US. Lam, Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer Paclitaxel resistance. Oncogene. 2016;35:990&#8211;1002. 10.1038/onc.2015.152.<pub-id pub-id-type="pmid">25961928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2015.152</pub-id><pub-id pub-id-type="pmcid">PMC4538879</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singel</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cornelius</surname><given-names>C</given-names></name><name name-style="western"><surname>Batten</surname><given-names>K</given-names></name><name name-style="western"><surname>Fasciani</surname><given-names>G</given-names></name><name name-style="western"><surname>Wright</surname><given-names>WE</given-names></name><name name-style="western"><surname>Lum</surname><given-names>L</given-names></name><name name-style="western"><surname>Shay</surname><given-names>JW</given-names></name></person-group><article-title>A targeted RNAi screen of the breast Cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in Triple-Negative breast cancer, clin</article-title><source>Cancer Res Off J Am Assoc Cancer Res</source><year>2013</year><volume>19</volume><fpage>2061</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0082</pub-id><pub-id pub-id-type="pmcid">PMC4513911</pub-id><pub-id pub-id-type="pmid">23479679</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Singel SM, Cornelius C, Batten K, Fasciani G, Wright WE, Lum L, Shay JW. A targeted RNAi screen of the breast Cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in Triple-Negative breast cancer, clin. Cancer Res Off J Am Assoc Cancer Res. 2013;19:2061&#8211;70. 10.1158/1078-0432.CCR-13-0082.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-13-0082</pub-id><pub-id pub-id-type="pmcid">PMC4513911</pub-id><pub-id pub-id-type="pmid">23479679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maliga</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>TM</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>TJ</given-names></name></person-group><article-title>Evidence that monastrol is an allosteric inhibitor of the mitotic Kinesin Eg5</article-title><source>Chem Biol</source><year>2002</year><volume>9</volume><fpage>989</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(02)00212-0</pub-id><pub-id pub-id-type="pmid">12323373</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Maliga Z, Kapoor TM, Mitchison TJ. Evidence that monastrol is an allosteric inhibitor of the mitotic Kinesin Eg5. Chem Biol. 2002;9:989&#8211;96. 10.1016/S1074-5521(02)00212-0.<pub-id pub-id-type="pmid">12323373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1074-5521(02)00212-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marques</surname><given-names>LA</given-names></name><name name-style="western"><surname>Semprebon</surname><given-names>SC</given-names></name><name name-style="western"><surname>Niwa</surname><given-names>AM</given-names></name><name name-style="western"><surname>D&#8217;Epiro</surname><given-names>GFR</given-names></name><name name-style="western"><surname>Sartori</surname><given-names>D</given-names></name><name name-style="western"><surname>de F&#225;tima</surname><given-names>&#194;</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>LR</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>MS</given-names></name></person-group><article-title>Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells, Naunyn</article-title><source>Schmiedebergs Arch Pharmacol</source><year>2016</year><volume>389</volume><fpage>1279</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s00210-016-1292-9</pub-id><pub-id pub-id-type="pmid">27592117</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Marques LA, Semprebon SC, Niwa AM, D&#8217;Epiro GFR, Sartori D, de F&#225;tima &#194;, Ribeiro LR, Mantovani MS. Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells, Naunyn. Schmiedebergs Arch Pharmacol. 2016;389:1279&#8211;88. 10.1007/s00210-016-1292-9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00210-016-1292-9</pub-id><pub-id pub-id-type="pmid">27592117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Su</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name></person-group><article-title>Circular RNA&#8211;MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis</article-title><source>Int J Oncol</source><year>2018</year><volume>53</volume><fpage>1752</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4485</pub-id><pub-id pub-id-type="pmid">30015883</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Liu Y, Dong Y, Zhao L, Su L, Luo J. Circular RNA&#8211;MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol. 2018;53:1752&#8211;62. 10.3892/ijo.2018.4485.<pub-id pub-id-type="pmid">30015883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2018.4485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghafouri-Fard</surname><given-names>S</given-names></name><name name-style="western"><surname>Khoshbakht</surname><given-names>T</given-names></name><name name-style="western"><surname>Bahranian</surname><given-names>A</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>M</given-names></name><name name-style="western"><surname>Hallajnejad</surname><given-names>M</given-names></name></person-group><article-title>CircMTO1: A circular RNA with roles in the carcinogenesis</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>142</volume><fpage>112025</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.112025</pub-id><pub-id pub-id-type="pmid">34392090</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Ghafouri-Fard S, Khoshbakht T, Bahranian A, Taheri M, Hallajnejad M. CircMTO1: A circular RNA with roles in the carcinogenesis. Biomed Pharmacother. 2021;142:112025. 10.1016/j.biopha.2021.112025.<pub-id pub-id-type="pmid">34392090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.112025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Denu</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sperger</surname><given-names>JM</given-names></name><name name-style="western"><surname>Schehr</surname><given-names>J</given-names></name><name name-style="western"><surname>Witkowsky</surname><given-names>T</given-names></name><name name-style="western"><surname>Esbona</surname><given-names>K</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>BA</given-names></name><name name-style="western"><surname>Burkard</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lang</surname><given-names>JM</given-names></name></person-group><article-title>Centrosome amplification is a frequent event in Circulating tumor cells from subjects with metastatic breast cancer</article-title><source>Mol Oncol</source><year>2020</year><volume>14</volume><fpage>1898</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12687</pub-id><pub-id pub-id-type="pmid">32255253</pub-id><pub-id pub-id-type="pmcid">PMC7400789</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Singh A, Denu RA, Wolfe SK, Sperger JM, Schehr J, Witkowsky T, Esbona K, Chappell RJ, Weaver BA, Burkard ME, Lang JM. Centrosome amplification is a frequent event in Circulating tumor cells from subjects with metastatic breast cancer. Mol Oncol. 2020;14:1898&#8211;909. 10.1002/1878-0261.12687.<pub-id pub-id-type="pmid">32255253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1878-0261.12687</pub-id><pub-id pub-id-type="pmcid">PMC7400789</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogden</surname><given-names>A</given-names></name><name name-style="western"><surname>Rida</surname><given-names>PCG</given-names></name><name name-style="western"><surname>Aneja</surname><given-names>R</given-names></name><name name-style="western"><surname>Amplification</surname><given-names>C</given-names></name></person-group><article-title>A suspect in breast Cancer and Racial disparities</article-title><source>Endocr Relat Cancer</source><year>2017</year><volume>24</volume><fpage>T47</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1530/ERC-17-0072</pub-id><pub-id pub-id-type="pmid">28515047</pub-id><pub-id pub-id-type="pmcid">PMC5837860</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Ogden A, Rida PCG, Aneja R, Amplification C. A suspect in breast Cancer and Racial disparities. Endocr Relat Cancer. 2017;24:T47&#8211;64. 10.1530/ERC-17-0072.<pub-id pub-id-type="pmid">28515047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/ERC-17-0072</pub-id><pub-id pub-id-type="pmcid">PMC5837860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name></person-group><article-title>Centrosome dysfunction: a link between senescence and tumor immunity, signal transduct</article-title><source>Target Ther</source><year>2020</year><volume>5</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41392-020-00214-7</pub-id><pub-id pub-id-type="pmcid">PMC7327052</pub-id><pub-id pub-id-type="pmid">32606370</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Wu Q, Li B, Liu L, Sun S, Sun S. Centrosome dysfunction: a link between senescence and tumor immunity, signal transduct. Target Ther. 2020;5:1&#8211;9. 10.1038/s41392-020-00214-7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00214-7</pub-id><pub-id pub-id-type="pmcid">PMC7327052</pub-id><pub-id pub-id-type="pmid">32606370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Centrosomal-associated proteins: potential therapeutic targets for solid tumors?</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>144</volume><fpage>112292</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.112292</pub-id><pub-id pub-id-type="pmid">34700231</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Luan Y, Li M, Zhao Y, Li Q, Wen J, Gao S, Yang Y. Centrosomal-associated proteins: potential therapeutic targets for solid tumors? Biomed Pharmacother. 2021;144:112292. 10.1016/j.biopha.2021.112292.<pub-id pub-id-type="pmid">34700231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.112292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denu</surname><given-names>RA</given-names></name><name name-style="western"><surname>Zasadil</surname><given-names>LM</given-names></name><name name-style="western"><surname>Kanugh</surname><given-names>C</given-names></name><name name-style="western"><surname>Laffin</surname><given-names>J</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>BA</given-names></name><name name-style="western"><surname>Burkard</surname><given-names>ME</given-names></name></person-group><article-title>Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer</article-title><source>BMC Cancer</source><year>2016</year><volume>16</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s12885-016-2083-x</pub-id><pub-id pub-id-type="pmcid">PMC4734858</pub-id><pub-id pub-id-type="pmid">26832928</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Denu RA, Zasadil LM, Kanugh C, Laffin J, Weaver BA, Burkard ME. Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. BMC Cancer. 2016;16:1&#8211;13. 10.1186/s12885-016-2083-x.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-016-2083-x</pub-id><pub-id pub-id-type="pmcid">PMC4734858</pub-id><pub-id pub-id-type="pmid">26832928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="other">Sepulveda G, Antkowiak M, Brust-Mascher I, Mahe K, Ou T, Castro NM, Christensen LN, Cheung L, Jiang X, Yoon D, Huang B, Jao L-E. Co-translational protein targeting facilitates centrosomal recruitment of PCNT during centrosome maturation in vertebrates. eLife. 2018;7. 10.7554/eLife.34959.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.34959</pub-id><pub-id pub-id-type="pmcid">PMC5976437</pub-id><pub-id pub-id-type="pmid">29708497</pub-id></mixed-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Splinter D, Tanenbaum ME, Lindqvist A, Jaarsma D, Flotho A, Yu KL, Grigoriev I, Engelsma D, Haasdijk ED, Keijzer N, Demmers J, Fornerod M, Melchior F, Hoogenraad CC, Medema RH, Akhmanova A. Bicaudal D2, dynein, and Kinesin-1 associate with nuclear pore complexes and regulate centrosome and nuclear positioning during mitotic entry. PLoS Biol. 2010;8. 10.1371/journal.pbio.1000350.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.1000350</pub-id><pub-id pub-id-type="pmcid">PMC2850381</pub-id><pub-id pub-id-type="pmid">20386726</pub-id></mixed-citation></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hata</surname><given-names>S</given-names></name><name name-style="western"><surname>Pastor Peidro</surname><given-names>A</given-names></name><name name-style="western"><surname>Panic</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Atorino</surname><given-names>E</given-names></name><name name-style="western"><surname>Funaya</surname><given-names>C</given-names></name><name name-style="western"><surname>J&#228;kle</surname><given-names>U</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>G</given-names></name><name name-style="western"><surname>Schiebel</surname><given-names>E</given-names></name></person-group><article-title>The balance between KIFC3 and EG5 tetrameric kinesins controls the onset of mitotic spindle assembly</article-title><source>Nat Cell Biol</source><year>2019</year><volume>21</volume><fpage>1138</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0382-6</pub-id><pub-id pub-id-type="pmid">31481795</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Hata S, Pastor Peidro A, Panic M, Liu P, Atorino E, Funaya C, J&#228;kle U, Pereira G, Schiebel E. The balance between KIFC3 and EG5 tetrameric kinesins controls the onset of mitotic spindle assembly. Nat Cell Biol. 2019;21:1138&#8211;51. 10.1038/s41556-019-0382-6.<pub-id pub-id-type="pmid">31481795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-019-0382-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>S</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H</given-names></name><name name-style="western"><surname>Takaoka</surname><given-names>M</given-names></name><name name-style="western"><surname>Miki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>A</given-names></name></person-group><article-title>BRCA2 mediates centrosome cohesion via an interaction with cytoplasmic dynein</article-title><source>Cell Cycle</source><year>2016</year><volume>15</volume><fpage>2145</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1080/15384101.2016.1195531</pub-id><pub-id pub-id-type="pmid">27433848</pub-id><pub-id pub-id-type="pmcid">PMC4993541</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Malik S, Saito H, Takaoka M, Miki Y, Nakanishi A. BRCA2 mediates centrosome cohesion via an interaction with cytoplasmic dynein. Cell Cycle. 2016;15:2145&#8211;56. 10.1080/15384101.2016.1195531.<pub-id pub-id-type="pmid">27433848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15384101.2016.1195531</pub-id><pub-id pub-id-type="pmcid">PMC4993541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eibes</surname><given-names>S</given-names></name><name name-style="western"><surname>Gallis&#224;-Su&#241;&#233;</surname><given-names>N</given-names></name><name name-style="western"><surname>Rosas-Salvans</surname><given-names>M</given-names></name><name name-style="western"><surname>Mart&#237;nez-Delgado</surname><given-names>P</given-names></name><name name-style="western"><surname>Vernos</surname><given-names>I</given-names></name><name name-style="western"><surname>Roig</surname><given-names>J</given-names></name></person-group><article-title>Nek9 phosphorylation defines a new role for TPX2 in Eg5-Dependent centrosome separation before nuclear envelope breakdown</article-title><source>Curr Biol CB</source><year>2018</year><volume>28</volume><fpage>121</fpage><lpage>e1294</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2017.11.046</pub-id><pub-id pub-id-type="pmid">29276125</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Eibes S, Gallis&#224;-Su&#241;&#233; N, Rosas-Salvans M, Mart&#237;nez-Delgado P, Vernos I, Roig J. Nek9 phosphorylation defines a new role for TPX2 in Eg5-Dependent centrosome separation before nuclear envelope breakdown. Curr Biol CB. 2018;28:121&#8211;e1294. 10.1016/j.cub.2017.11.046.<pub-id pub-id-type="pmid">29276125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2017.11.046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Ree</surname><given-names>JH</given-names></name><name name-style="western"><surname>Nam</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Jeganathan</surname><given-names>KB</given-names></name><name name-style="western"><surname>Kanakkanthara</surname><given-names>A</given-names></name><name name-style="western"><surname>van Deursen</surname><given-names>JM</given-names></name></person-group><article-title>Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes</article-title><source>Nat Cell Biol</source><year>2016</year><volume>18</volume><fpage>814</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/ncb3369</pub-id><pub-id pub-id-type="pmid">27240320</pub-id><pub-id pub-id-type="pmcid">PMC5004208</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">van Ree JH, Nam H-J, Jeganathan KB, Kanakkanthara A, van Deursen JM. Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes. Nat Cell Biol. 2016;18:814&#8211;21. 10.1038/ncb3369.<pub-id pub-id-type="pmid">27240320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncb3369</pub-id><pub-id pub-id-type="pmcid">PMC5004208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinemann</surname><given-names>DN</given-names></name><name name-style="western"><surname>Sturgill</surname><given-names>EG</given-names></name><name name-style="western"><surname>Das</surname><given-names>DK</given-names></name><name name-style="western"><surname>Degen</surname><given-names>MS</given-names></name><name name-style="western"><surname>V&#246;r&#246;s</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ohi</surname><given-names>R</given-names></name><name name-style="western"><surname>Lang</surname><given-names>MJ</given-names></name></person-group><article-title>Collective force regulation in Anti-parallel microtubule gliding by dimeric Kif15 Kinesin motors</article-title><source>Curr Biol CB</source><year>2017</year><volume>27</volume><fpage>2810</fpage><lpage>e28206</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2017.08.018</pub-id><pub-id pub-id-type="pmid">28918951</pub-id><pub-id pub-id-type="pmcid">PMC5909953</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Reinemann DN, Sturgill EG, Das DK, Degen MS, V&#246;r&#246;s Z, Hwang W, Ohi R, Lang MJ. Collective force regulation in Anti-parallel microtubule gliding by dimeric Kif15 Kinesin motors. Curr Biol CB. 2017;27:2810&#8211;e28206. 10.1016/j.cub.2017.08.018.<pub-id pub-id-type="pmid">28918951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2017.08.018</pub-id><pub-id pub-id-type="pmcid">PMC5909953</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanenbaum</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mac&#367;rek</surname><given-names>L</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>A</given-names></name><name name-style="western"><surname>Geers</surname><given-names>EF</given-names></name><name name-style="western"><surname>Alvarez-Fern&#225;ndez</surname><given-names>M</given-names></name><name name-style="western"><surname>Medema</surname><given-names>RH</given-names></name></person-group><article-title>Kif15 cooperates with Eg5 to promote bipolar spindle assembly</article-title><source>Curr Biol</source><year>2009</year><volume>19</volume><fpage>1703</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2009.08.027</pub-id><pub-id pub-id-type="pmid">19818618</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Tanenbaum ME, Mac&#367;rek L, Janssen A, Geers EF, Alvarez-Fern&#225;ndez M, Medema RH. Kif15 cooperates with Eg5 to promote bipolar spindle assembly. Curr Biol. 2009;19:1703&#8211;11. 10.1016/j.cub.2009.08.027.<pub-id pub-id-type="pmid">19818618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2009.08.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drosopoulos</surname><given-names>K</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><name name-style="western"><surname>Chao</surname><given-names>WCH</given-names></name><name name-style="western"><surname>Linardopoulos</surname><given-names>S</given-names></name></person-group><article-title>APC/C is an essential regulator of centrosome clustering</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/ncomms4686</pub-id><pub-id pub-id-type="pmid">24751481</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Drosopoulos K, Tang C, Chao WCH, Linardopoulos S. APC/C is an essential regulator of centrosome clustering. Nat Commun. 2014;5:1&#8211;13. 10.1038/ncomms4686.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms4686</pub-id><pub-id pub-id-type="pmid">24751481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>A</given-names></name><name name-style="western"><surname>Dictenberg</surname><given-names>JB</given-names></name><name name-style="western"><surname>Purohit</surname><given-names>A</given-names></name><name name-style="western"><surname>Tuft</surname><given-names>R</given-names></name><name name-style="western"><surname>Doxsey</surname><given-names>SJ</given-names></name></person-group><article-title>Cytoplasmic dynein-mediated assembly of pericentrin and gamma tubulin onto centrosomes</article-title><source>Mol Biol Cell</source><year>2000</year><volume>11</volume><fpage>2047</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1091/mbc.11.6.2047</pub-id><pub-id pub-id-type="pmid">10848628</pub-id><pub-id pub-id-type="pmcid">PMC14902</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Young A, Dictenberg JB, Purohit A, Tuft R, Doxsey SJ. Cytoplasmic dynein-mediated assembly of pericentrin and gamma tubulin onto centrosomes. Mol Biol Cell. 2000;11:2047&#8211;56. 10.1091/mbc.11.6.2047.<pub-id pub-id-type="pmid">10848628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.11.6.2047</pub-id><pub-id pub-id-type="pmcid">PMC14902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="other">Vitre B, Taulet N, Guesdon A, Douanier A, Dosdane A, Cisneros M, Maurin J, Hettinger S, Anguille C, Taschner M, Lorentzen E, Delaval B. IFT proteins interact with HSET to promote supernumerary centrosome clustering in mitosis. EMBO Rep N/a. 2020;e49234. 10.15252/embr.201949234.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.201949234</pub-id><pub-id pub-id-type="pmcid">PMC7271317</pub-id><pub-id pub-id-type="pmid">32270908</pub-id></mixed-citation></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquis</surname><given-names>C</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>CL</given-names></name><name name-style="western"><surname>Queen</surname><given-names>KA</given-names></name><name name-style="western"><surname>Wood</surname><given-names>L</given-names></name><name name-style="western"><surname>Vandal</surname><given-names>SE</given-names></name><name name-style="western"><surname>Malaby</surname><given-names>HLH</given-names></name><name name-style="western"><surname>Clayton</surname><given-names>JE</given-names></name><name name-style="western"><surname>Stumpff</surname><given-names>J</given-names></name></person-group><article-title>Chromosomally unstable tumor cells specifically require KIF18A for proliferation</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>1213</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21447-2</pub-id><pub-id pub-id-type="pmid">33619254</pub-id><pub-id pub-id-type="pmcid">PMC7900194</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Marquis C, Fonseca CL, Queen KA, Wood L, Vandal SE, Malaby HLH, Clayton JE, Stumpff J. Chromosomally unstable tumor cells specifically require KIF18A for proliferation. Nat Commun. 2021;12:1213. 10.1038/s41467-021-21447-2.<pub-id pub-id-type="pmid">33619254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21447-2</pub-id><pub-id pub-id-type="pmcid">PMC7900194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamagiwa</surname><given-names>A</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>T</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>H</given-names></name><name name-style="western"><surname>Ono</surname><given-names>Y</given-names></name><name name-style="western"><surname>Centrosomal Proteins</surname><given-names>CG-NAP</given-names></name></person-group><article-title>Kendrin provide microtubule nucleation sites by anchoring &#947;-Tubulin ring complex</article-title><source>Mol Biol Cell</source><year>2002</year><volume>13</volume><fpage>3235</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1091/mbc.E02-02-0112</pub-id><pub-id pub-id-type="pmid">12221128</pub-id><pub-id pub-id-type="pmcid">PMC124155</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Takahashi M, Yamagiwa A, Nishimura T, Mukai H, Ono Y, Centrosomal Proteins CG-NAP. Kendrin provide microtubule nucleation sites by anchoring &#947;-Tubulin ring complex. Mol Biol Cell. 2002;13:3235&#8211;45. 10.1091/mbc.E02-02-0112.<pub-id pub-id-type="pmid">12221128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.E02-02-0112</pub-id><pub-id pub-id-type="pmcid">PMC124155</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Ketcham</surname><given-names>SA</given-names></name><name name-style="western"><surname>Schroer</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lander</surname><given-names>GC</given-names></name></person-group><article-title>Structural organization of the dynein-dynactin complex bound to microtubules</article-title><source>Nat Struct Mol Biol</source><year>2015</year><volume>22</volume><fpage>345</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2996</pub-id><pub-id pub-id-type="pmid">25751425</pub-id><pub-id pub-id-type="pmcid">PMC4385409</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Chowdhury S, Ketcham SA, Schroer TA, Lander GC. Structural organization of the dynein-dynactin complex bound to microtubules. Nat Struct Mol Biol. 2015;22:345&#8211;7. 10.1038/nsmb.2996.<pub-id pub-id-type="pmid">25751425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nsmb.2996</pub-id><pub-id pub-id-type="pmcid">PMC4385409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanenbaum</surname><given-names>ME</given-names></name><name name-style="western"><surname>Medema</surname><given-names>RH</given-names></name></person-group><article-title>Mechanisms of centrosome separation and bipolar spindle assembly</article-title><source>Dev Cell</source><year>2010</year><volume>19</volume><fpage>797</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2010.11.011</pub-id><pub-id pub-id-type="pmid">21145497</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Tanenbaum ME, Medema RH. Mechanisms of centrosome separation and bipolar spindle assembly. Dev Cell. 2010;19:797&#8211;806. 10.1016/j.devcel.2010.11.011.<pub-id pub-id-type="pmid">21145497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2010.11.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vicente</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wordeman</surname><given-names>L</given-names></name></person-group><article-title>Mitosis, microtubule dynamics and the evolution of kinesins, exp</article-title><source>Cell Res</source><year>2015</year><volume>334</volume><fpage>61</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2015.02.010</pub-id><pub-id pub-id-type="pmcid">PMC4433793</pub-id><pub-id pub-id-type="pmid">25708751</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Vicente JJ, Wordeman L. Mitosis, microtubule dynamics and the evolution of kinesins, exp. Cell Res. 2015;334:61&#8211;9. 10.1016/j.yexcr.2015.02.010.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexcr.2015.02.010</pub-id><pub-id pub-id-type="pmcid">PMC4433793</pub-id><pub-id pub-id-type="pmid">25708751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Heesbeen</surname><given-names>RGHP</given-names></name><name name-style="western"><surname>Raaijmakers</surname><given-names>JA</given-names></name><name name-style="western"><surname>Tanenbaum</surname><given-names>ME</given-names></name><name name-style="western"><surname>Halim</surname><given-names>VA</given-names></name><name name-style="western"><surname>Lelieveld</surname><given-names>D</given-names></name><name name-style="western"><surname>Lieftink</surname><given-names>C</given-names></name><name name-style="western"><surname>Heck</surname><given-names>AJR</given-names></name><name name-style="western"><surname>Egan</surname><given-names>DA</given-names></name><name name-style="western"><surname>Medema</surname><given-names>RH</given-names></name></person-group><article-title>Aurora A, MCAK, and Kif18b promote Eg5-independent spindle formation</article-title><source>Chromosoma</source><year>2017</year><volume>126</volume><fpage>473</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00412-016-0607-4</pub-id><pub-id pub-id-type="pmid">27354041</pub-id><pub-id pub-id-type="pmcid">PMC5509784</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">van Heesbeen RGHP, Raaijmakers JA, Tanenbaum ME, Halim VA, Lelieveld D, Lieftink C, Heck AJR, Egan DA, Medema RH. Aurora A, MCAK, and Kif18b promote Eg5-independent spindle formation. Chromosoma. 2017;126:473&#8211;86. 10.1007/s00412-016-0607-4.<pub-id pub-id-type="pmid">27354041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00412-016-0607-4</pub-id><pub-id pub-id-type="pmcid">PMC5509784</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>